WO2010118761A1 - Compositions rich in omega-3 fatty acids with a low content in phytanic acid - Google Patents
Compositions rich in omega-3 fatty acids with a low content in phytanic acid Download PDFInfo
- Publication number
- WO2010118761A1 WO2010118761A1 PCT/EP2009/002842 EP2009002842W WO2010118761A1 WO 2010118761 A1 WO2010118761 A1 WO 2010118761A1 EP 2009002842 W EP2009002842 W EP 2009002842W WO 2010118761 A1 WO2010118761 A1 WO 2010118761A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dha
- pha
- syndrome
- fatty acids
- treatment
- Prior art date
Links
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 137
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- 239000006014 omega-3 oil Substances 0.000 title claims abstract description 95
- 229940012843 omega-3 fatty acid Drugs 0.000 title claims abstract description 93
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 title abstract description 384
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 title abstract description 378
- 238000000034 method Methods 0.000 claims abstract description 175
- 239000003921 oil Substances 0.000 claims abstract description 170
- 235000016709 nutrition Nutrition 0.000 claims abstract description 14
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 156
- 238000011282 treatment Methods 0.000 claims description 106
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 102
- 229930195729 fatty acid Natural products 0.000 claims description 102
- 239000000194 fatty acid Substances 0.000 claims description 102
- 150000004665 fatty acids Chemical class 0.000 claims description 95
- 230000008569 process Effects 0.000 claims description 71
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 238000004519 manufacturing process Methods 0.000 claims description 53
- 230000004304 visual acuity Effects 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 48
- 230000002265 prevention Effects 0.000 claims description 45
- 238000002425 crystallisation Methods 0.000 claims description 44
- 208000011580 syndromic disease Diseases 0.000 claims description 42
- 230000001965 increasing effect Effects 0.000 claims description 38
- 150000003626 triacylglycerols Chemical class 0.000 claims description 36
- 238000005199 ultracentrifugation Methods 0.000 claims description 35
- 230000004075 alteration Effects 0.000 claims description 33
- 235000013305 food Nutrition 0.000 claims description 28
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 27
- 238000007254 oxidation reaction Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 230000007812 deficiency Effects 0.000 claims description 19
- 239000007791 liquid phase Substances 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 210000001525 retina Anatomy 0.000 claims description 18
- -1 fatty acids salts Chemical class 0.000 claims description 17
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 17
- 230000009885 systemic effect Effects 0.000 claims description 17
- 206010046851 Uveitis Diseases 0.000 claims description 16
- 238000007127 saponification reaction Methods 0.000 claims description 16
- 231100000331 toxic Toxicity 0.000 claims description 16
- 230000002588 toxic effect Effects 0.000 claims description 16
- 239000007790 solid phase Substances 0.000 claims description 15
- 210000001508 eye Anatomy 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000000302 ischemic effect Effects 0.000 claims description 11
- 208000001491 myopia Diseases 0.000 claims description 11
- 230000004379 myopia Effects 0.000 claims description 11
- 230000002207 retinal effect Effects 0.000 claims description 11
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 10
- 239000012298 atmosphere Substances 0.000 claims description 10
- 230000007547 defect Effects 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 208000005587 Refsum Disease Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 206010061876 Obstruction Diseases 0.000 claims description 8
- 208000027073 Stargardt disease Diseases 0.000 claims description 8
- 208000030597 adult Refsum disease Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 230000020477 pH reduction Effects 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 7
- 230000000858 peroxisomal effect Effects 0.000 claims description 7
- 206010003591 Ataxia Diseases 0.000 claims description 6
- 208000002691 Choroiditis Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000004788 Pars Planitis Diseases 0.000 claims description 6
- 208000003971 Posterior uveitis Diseases 0.000 claims description 6
- 206010038848 Retinal detachment Diseases 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 6
- 208000014769 Usher Syndromes Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052753 mercury Inorganic materials 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 201000007714 retinoschisis Diseases 0.000 claims description 6
- 206010027654 Allergic conditions Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 230000006735 deficit Effects 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 4
- 208000033810 Choroidal dystrophy Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010022941 Iridocyclitis Diseases 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000020547 Peroxisomal disease Diseases 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 201000004964 Rhizomelic Chondrodysplasia Punctata Diseases 0.000 claims description 4
- 208000029977 White Dot Syndromes Diseases 0.000 claims description 4
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 4
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims description 4
- 201000004612 anterior uveitis Diseases 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 4
- 230000002146 bilateral effect Effects 0.000 claims description 4
- 208000003571 choroideremia Diseases 0.000 claims description 4
- 230000002008 hemorrhagic effect Effects 0.000 claims description 4
- 230000001631 hypertensive effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000000366 juvenile effect Effects 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 210000001927 retinal artery Anatomy 0.000 claims description 4
- 230000004264 retinal detachment Effects 0.000 claims description 4
- 230000001173 tumoral effect Effects 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010011033 Corneal oedema Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 3
- 206010058314 Dysplasia Diseases 0.000 claims description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 201000006328 Fanconi syndrome Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 3
- 208000006136 Leigh Disease Diseases 0.000 claims description 3
- 208000017507 Leigh syndrome Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 3
- 208000018909 Neonatal adrenoleukodystrophy Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 201000002996 androgenic alopecia Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 201000004709 chorioretinitis Diseases 0.000 claims description 3
- 201000004778 corneal edema Diseases 0.000 claims description 3
- 238000010908 decantation Methods 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 230000002438 mitochondrial effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 230000000474 nursing effect Effects 0.000 claims description 3
- 230000000771 oncological effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 201000010041 presbyopia Diseases 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 230000032258 transport Effects 0.000 claims description 3
- 201000007994 Aceruloplasminemia Diseases 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010000598 Acrodynia Diseases 0.000 claims description 2
- 231100000455 Acrodynia Toxicity 0.000 claims description 2
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 claims description 2
- 108020001558 Acyl-CoA oxidase Proteins 0.000 claims description 2
- 208000008286 Aortic Arch Syndromes Diseases 0.000 claims description 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims description 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims description 2
- 108010083590 Apoproteins Proteins 0.000 claims description 2
- 102000006410 Apoproteins Human genes 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000033258 Bifunctional enzyme deficiency Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006500 Brucellosis Diseases 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 206010007134 Candida infections Diseases 0.000 claims description 2
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000014085 Chronic respiratory disease Diseases 0.000 claims description 2
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000024539 Diencephalic syndrome Diseases 0.000 claims description 2
- 208000016974 Eales' disease Diseases 0.000 claims description 2
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 2
- 108700000224 Familial apoceruloplasmin deficiency Proteins 0.000 claims description 2
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 206010061958 Food Intolerance Diseases 0.000 claims description 2
- 208000024160 Fuchs heterochromic iridocyclitis Diseases 0.000 claims description 2
- 201000010479 Fuchs' heterochromic uveitis Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 208000008498 Infantile Refsum disease Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 claims description 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 208000002838 Juvenile Xanthogranuloma Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000001126 Keratosis Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010025476 Malabsorption Diseases 0.000 claims description 2
- 206010026865 Mass Diseases 0.000 claims description 2
- 208000030527 Minamata disease Diseases 0.000 claims description 2
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 206010029113 Neovascularisation Diseases 0.000 claims description 2
- 208000009507 Nervous System Mercury Poisoning Diseases 0.000 claims description 2
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030216 Oesophagitis Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 2
- 206010061323 Optic neuropathy Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000027032 Renal vascular disease Diseases 0.000 claims description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims description 2
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 claims description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 2
- 206010072610 Skeletal dysplasia Diseases 0.000 claims description 2
- 208000027077 Stickler syndrome Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 206010044269 Toxocariasis Diseases 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
- 206010047513 Vision blurred Diseases 0.000 claims description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims description 2
- 206010047663 Vitritis Diseases 0.000 claims description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 2
- 208000027207 Whipple disease Diseases 0.000 claims description 2
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 claims description 2
- 208000017441 X-linked retinoschisis Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000019672 acute posterior multifocal placoid pigment epitheliopathy Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 229940124522 antiretrovirals Drugs 0.000 claims description 2
- 210000001742 aqueous humor Anatomy 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010072959 birdshot chorioretinopathy Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 201000005668 blepharoconjunctivitis Diseases 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 201000003984 candidiasis Diseases 0.000 claims description 2
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 208000026915 cervical aortic arch Diseases 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000009852 coagulant defect Effects 0.000 claims description 2
- 230000003920 cognitive function Effects 0.000 claims description 2
- 210000000795 conjunctiva Anatomy 0.000 claims description 2
- 208000021921 corneal disease Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 230000008998 dermatological alteration Effects 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 206010014801 endophthalmitis Diseases 0.000 claims description 2
- 208000020947 enthesitis Diseases 0.000 claims description 2
- 208000006881 esophagitis Diseases 0.000 claims description 2
- 210000000744 eyelid Anatomy 0.000 claims description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000007686 hepatotoxicity Effects 0.000 claims description 2
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 2
- 208000013653 hyalitis Diseases 0.000 claims description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 230000003870 intestinal permeability Effects 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000006386 memory function Effects 0.000 claims description 2
- 230000006609 metabolic stress Effects 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 230000002232 neuromuscular Effects 0.000 claims description 2
- 201000002165 neuroretinitis Diseases 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 210000000869 occipital lobe Anatomy 0.000 claims description 2
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
- 208000020911 optic nerve disease Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000007407 panuveitis Diseases 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 208000021278 peroxisomal biogenesis disease Diseases 0.000 claims description 2
- 208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000003004 ptosis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 208000015670 renal artery disease Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 2
- 230000037078 sports performance Effects 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 201000010371 vitreoretinal dystrophy Diseases 0.000 claims description 2
- 208000000318 vitreous detachment Diseases 0.000 claims description 2
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 claims 2
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 claims 2
- 206010068783 Alstroem syndrome Diseases 0.000 claims 1
- 201000005932 Alstrom Syndrome Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 claims 1
- 201000006360 Edwards syndrome Diseases 0.000 claims 1
- 208000015178 Hurler syndrome Diseases 0.000 claims 1
- 208000019468 Iatrogenic Disease Diseases 0.000 claims 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims 1
- 208000035023 Oculocerebrorenal syndrome of Lowe Diseases 0.000 claims 1
- 206010039729 Scotoma Diseases 0.000 claims 1
- 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 claims 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000026621 hypolipoproteinemia Diseases 0.000 claims 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims 1
- 201000006352 oculocerebrorenal syndrome Diseases 0.000 claims 1
- 201000003738 orofaciodigital syndrome VIII Diseases 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 206010053884 trisomy 18 Diseases 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 25
- 230000009471 action Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 229940127557 pharmaceutical product Drugs 0.000 abstract description 3
- 230000000069 prophylactic effect Effects 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 704
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 352
- 229940090949 docosahexaenoic acid Drugs 0.000 description 351
- 235000019198 oils Nutrition 0.000 description 163
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 82
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 80
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 80
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 80
- PAHGJZDQXIOYTH-UHFFFAOYSA-N pristanic acid Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O PAHGJZDQXIOYTH-UHFFFAOYSA-N 0.000 description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 230000008025 crystallization Effects 0.000 description 38
- 239000012071 phase Substances 0.000 description 37
- 238000000926 separation method Methods 0.000 description 32
- 235000021588 free fatty acids Nutrition 0.000 description 31
- 108091008695 photoreceptors Proteins 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 27
- 230000006907 apoptotic process Effects 0.000 description 26
- 238000005119 centrifugation Methods 0.000 description 26
- 239000007788 liquid Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 23
- 235000019688 fish Nutrition 0.000 description 22
- 241000251468 Actinopterygii Species 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 235000005911 diet Nutrition 0.000 description 19
- 230000037213 diet Effects 0.000 description 19
- 230000003647 oxidation Effects 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 230000005496 eutectics Effects 0.000 description 18
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 235000021323 fish oil Nutrition 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 230000007062 hydrolysis Effects 0.000 description 15
- 238000006460 hydrolysis reaction Methods 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 208000032430 Retinal dystrophy Diseases 0.000 description 14
- 238000001640 fractional crystallisation Methods 0.000 description 14
- 150000003904 phospholipids Chemical class 0.000 description 14
- 230000000007 visual effect Effects 0.000 description 14
- 239000003925 fat Substances 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000005194 fractionation Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 230000032050 esterification Effects 0.000 description 11
- 238000005886 esterification reaction Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 230000004382 visual function Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 9
- 101710110781 Guanylate-binding protein 1 Proteins 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000004332 deodorization Methods 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 229940013317 fish oils Drugs 0.000 description 9
- 238000007670 refining Methods 0.000 description 9
- 235000019157 thiamine Nutrition 0.000 description 9
- 239000011721 thiamine Substances 0.000 description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 8
- 241000195493 Cryptophyta Species 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 230000002424 anti-apoptotic effect Effects 0.000 description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000032578 Inherited retinal disease Diseases 0.000 description 6
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 6
- 241001290266 Sciaenops ocellatus Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 201000006321 fundus dystrophy Diseases 0.000 description 6
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000016732 phototransduction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005809 transesterification reaction Methods 0.000 description 6
- 241000239366 Euphausiacea Species 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 238000001738 isopycnic centrifugation Methods 0.000 description 5
- 235000019421 lipase Nutrition 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000000199 molecular distillation Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 4
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 102000003849 Cytochrome P450 Human genes 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 102000004330 Rhodopsin Human genes 0.000 description 4
- 108090000820 Rhodopsin Proteins 0.000 description 4
- 230000006909 anti-apoptosis Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000013350 formula milk Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 229940040461 lipase Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 230000009291 secondary effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 108091007065 BIRCs Proteins 0.000 description 3
- 102000002263 Cytochrome P-450 CYP2C8 Human genes 0.000 description 3
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 3
- 241000598397 Schizochytrium sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 231100000895 deafness Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 210000000540 fraction c Anatomy 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 238000011194 good manufacturing practice Methods 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 235000006486 human diet Nutrition 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002248 lipoperoxidative effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 3
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical class C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- PVEJIIYHUJZERF-UHFFFAOYSA-N 1,4-dioxine;furan Chemical class C=1C=COC=1.O1C=COC=C1 PVEJIIYHUJZERF-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000276438 Gadus morhua Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- 231100000457 cardiotoxic Toxicity 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 235000019516 cod Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000093 cytochemical effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 150000002013 dioxins Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 235000020988 fatty fish Nutrition 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000001277 hydride generation atomic absorption spectroscopy Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- AOHAPDDBNAPPIN-UHFFFAOYSA-N myristicinic acid Natural products COC1=CC(C(O)=O)=CC2=C1OCO2 AOHAPDDBNAPPIN-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 108010093489 thiaminase II Proteins 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- DJRSBBCVHHMMLH-ZAJAATJQSA-N (2e,4e,6e)-deca-2,4,6-trienal Chemical compound CCC\C=C\C=C\C=C\C=O DJRSBBCVHHMMLH-ZAJAATJQSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- MORUQNQGRSLTCD-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;zinc Chemical compound [Zn].NCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 MORUQNQGRSLTCD-FJXQXJEOSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NDFKTBCGKNOHPJ-AATRIKPKSA-N (E)-hept-2-enal Chemical compound CCCC\C=C\C=O NDFKTBCGKNOHPJ-AATRIKPKSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- AGCPZMJBXSCWQY-UHFFFAOYSA-N 1,1,2,3,4-pentachlorobutane Chemical compound ClCC(Cl)C(Cl)C(Cl)Cl AGCPZMJBXSCWQY-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- DMVBWVASDWGFNH-UHFFFAOYSA-M 2-[1-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-methylpyridin-1-ium-3-yl]ethanol;hydron;dibromide Chemical compound Br.[Br-].NC1=NC(C)=NC=C1C[N+]1=CC=CC(CCO)=C1C DMVBWVASDWGFNH-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100442689 Caenorhabditis elegans hdl-1 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241001282408 Crypthecodinium sp. Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010066054 Dysmorphism Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 241000178983 Euglena sp. Species 0.000 description 1
- 241000239370 Euphausia superba Species 0.000 description 1
- 241000004871 Evernia Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102100028541 Guanylate-binding protein 2 Human genes 0.000 description 1
- 101710110789 Guanylate-binding protein 2 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101001010832 Homo sapiens Non-homologous end joining factor IFFO1 Proteins 0.000 description 1
- 241001504070 Huperzia Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102100029980 Non-homologous end joining factor IFFO1 Human genes 0.000 description 1
- 108010084311 Novozyme 435 Proteins 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 102000042022 Rab family Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 208000004453 Retinal Dysplasia Diseases 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000500637 Sebastes sp. Species 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000269849 Thunnus Species 0.000 description 1
- 241000405932 Thynnus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241001298226 Ulkenia sp. Species 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000416 anti-micotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000012076 audiometry Methods 0.000 description 1
- 206010003882 axonal neuropathy Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 208000001020 chondrodysplasia punctata Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- VGFCHANRXLYUOQ-UHFFFAOYSA-N delphidine Natural products OC1C2C3C4(C5C6OC)C(O)CCC5(COC)CN(CC)C4C6C2(OC(C)=O)CC(OC)C1C3 VGFCHANRXLYUOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002575 demyelinative effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000003943 differential pulse anodic stripping voltammetry Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960001342 dinoprost Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- XJFYWGIWEYQMPK-UHFFFAOYSA-N ethanol;urea Chemical compound CCO.NC(N)=O XJFYWGIWEYQMPK-UHFFFAOYSA-N 0.000 description 1
- ITNKVODZACVXDS-YATCGRJWSA-N ethyl (4e,7e,10e,13e,16e,19e)-docosa-4,7,10,13,16,19-hexaenoate Chemical compound CCOC(=O)CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CC ITNKVODZACVXDS-YATCGRJWSA-N 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000021191 food habits Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- SATICYYAWWYRAM-UHFFFAOYSA-N hepta-2,4-dienal Chemical compound CCC=CC=CC=O SATICYYAWWYRAM-UHFFFAOYSA-N 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- NDFKTBCGKNOHPJ-UHFFFAOYSA-N hex-2-enal Natural products CCCCC=CC=O NDFKTBCGKNOHPJ-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000021032 oily fish Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 102000016949 rab GTP-Binding Proteins Human genes 0.000 description 1
- 108010014420 rab GTP-Binding Proteins Proteins 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 231100000390 retinotoxic Toxicity 0.000 description 1
- 230000000448 retinotoxic effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- JUVIOZPCNVVQFO-HBGVWJBISA-N rotenone Chemical compound O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000004061 uncoupling agent Substances 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
- C11C1/025—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by saponification and release of fatty acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/08—Refining
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the current invention refers to the procedure to obtain compositions rich in omega 3 fatty acids with content in phytanic acid below 90 ⁇ g per gram of oil.
- the current invention also refers to the obtaining of compositions rich in DHA with a content in phytanic acid below 90 ⁇ g per gram of oil, more specifically between 650-950 mg/g, that is, between 65% and 95% of DHA in weight and values of PhA below 90 ⁇ g, preferably below 5 ⁇ g per gram of the oil forming the composition.
- the compositions obtained are used in the field of food supplements, nutritional products and pharmaceutical products due to their prophylactic action and therapeutic effect.
- Omega 3 fatty acids are a family of polyunsaturated fatty acids whose common feature is that the last double bond is located in the third C-C bond starting from the final methyl group of the fatty acid. Omega 3 fatty acids are essential, that is, the human body cannot produce them internally and therefore it is necessary to take them through the diet or through compositions. Due to their polyunsaturated nature, omega 3 fatty acids have very particular physicochemical functions in the human body (ie. very low melting point) and therefore they have been widely studied. Today, it is known that there are up to 10 omega 3 fatty acids (ie. stearic acid), although their presence in the human body is in very small amounts and their physiological activity is very low or absent, except for DHA and/or EPA.
- omega 3 fatty acids ie. stearic acid
- the acid 5,8,11,14,17-eicosapentaenoic or EPA, as well as 4,7,11 ,13,16,19- docosahexaenoic or DHA are the omega 3 fatty acids with most physiological functions, specially DHA, which has specific functions in retina, sperm, neural tissue etc. Both DHA and EPA have common physiological functions, although DHA has specific physiological functions that no other fatty acid has, particularly in photoreceptors, neural tissue and sperm amongst others. The intake of high doses of DHA increases the levels of EPA 1 although the reverse does not happen; in addition, DHA does not alter the synthesis of other fatty acids (Voss et al., 1992).
- DHA is the most interesting omega 3 fatty acid from the biological viewpoint for human consumption. Since DHA and EPA are present in the same food sources and since EPA is more abundant, initially EPA has been the one that has called more attention, being easier to obtain. However, knowledge on these two fatty acids over the last 15 years has significantly increased the interest for DHA and for its necessary purification since, aside from exceptions, at the most it is present in no more than 10-15% of the fats in the most abundant food sources.
- omega 3 fatty acids rich in DHA are of marine origin: microalgae (ie. Schizochytrium sp., Crypthecodinium sp., Ulkenia sp., Euglena sp.), crustaceans (ie. krill Euphausia superba), fatty fish (ie. Thunnus ibynnus thynnus or red tunna), and marine mammals; in addition to mushrooms and yeast (ie. Yarrowia lipolytica) and bacterias (ie. Lactobacillus spp.).
- microalgae ie. Schizochytrium sp., Crypthecodinium sp., Ulkenia sp., Euglena sp.
- crustaceans ie. krill Euphausia superba
- fatty fish ie. Thunnus ibynnus thynnus or red tunna
- yeast
- the most abundant source with the highest purity and most adequate for obtaining omega 3 fatty acids rich in DHA for human consumption is fish, since the production is of 140 million Tons of fish and shellfish per year (FAO, 2007) and it is estimated that the production of fish oil accounts for 1 million metric tonnes yearly (IFFO, International Fishmeal & Fish oil Organisation).
- the most suitable fish is tunna and other species with the highest content of Omega 3, being the percentage of DHA beyond 20 % in weight; besides, since they are food products they exhibit the highest guarantee and safety in public health.
- krill represents the largest reserve and biomass of DHA of the planet.
- omega 3 fatty acids represent a serious and known risk for trophic chains and the development of species and fish necessary for the human diet.
- a possibility in the future would be obtaining such krill in krill farms, where there would be no risk for the trophic chains and in addition, they could reproduce in an environment free from contaminants that would normally exist in marine waters.
- DHA is a deficient nutrient in most diets worldwide. But, in addition to its relevance as a treatment in DHA deficient diseases, its physiological action makes it into the most relevant cofactor for the treatment and prevention of neurodegenerative disease such as Alzheimer or schizophrenia; retina degenerative diseases, cancer, autoimmune diseases, chronic articular and dermatologic inflammatory diseases, renal and urologic diseases (prostate), androgenic alopecia, alterations in male and female fertility, primary attention disorder or hyperactivity, intellectual and cognitive development, as well as necessary for the visual development and particularly of the macular region, cardiovascular diseases, diabetes and hypertriglyceridemia.
- neurodegenerative disease such as Alzheimer or schizophrenia
- Polyunsaturated fatty acids are highly unstable in their free form, so their oral uptake requires stabilisation, which can be achieved through esterification or link to other molecules such as glycerol and ethanol, that makes them more stable and increases their bioavailability.
- the first vehicle (glycerol) enables a higher purity (triglyceride), stability and exhibits a maximum bioavailability, avoiding the presence of alcohol, which is particularly important in cases where high doses are required and when, in numerous applications, its use is chronic, in addition to pregnant women and children.
- Triglycerides are ingested in concentrations hundreds of times higher as part of the normal food and are the natural nutritional source and pharmacokinetics of fatty acids in target tissues. The pharmacokinetics of triglycerides is maximum and it enables the maximum purity of the active substance, DHA, and therefore DHA triglycerides exhibit the best absorption and have more physiological and metabolic implications.
- the synthesis of fatty acids and the trophic chain in living organisms are responsible for the physicochemica! properties of the membranes and their physiological adaptation to the environmental conditions (ie. temperature).
- the fatty acids with the lowest fusion point (FP) found in phospholipids and fats of living organisms are pristanic acid (PA), phytanic acid (PhA), EPA 1 DHA, arachidonic acid (AA) and estearic acid (SDA), which grant optimal physiological conditions under low temperatures.
- Organisms use two chemical strategies to obtain fatty acids with a very low FP: methylation and the unsaturation of carboxylic acids.
- the fatty acids with the lowest FP encountered in nature, foods and in the fatty derived products such as oils of marine origin are the long branch chain fatty acids (C>18) with several methyl groups, from which PhA is the one present in the highest concentrations and the long chain lineal omega 3 fatty acids (C>18), where the two most relevant ones due to their concentration and abundance are DHA and EPA.
- PhA is present in the human diet or in animal tissues where it can get through the chlorophyll of plants. PhA is formed from the corresponding alcohol, phytol and is oxidised to form PA 1 which explains why it is usual to find PA and PhA together. PhA is involved in one human pathology, Refsums Syndrome, which is characterised by an accumulation of PhA in the blood and tissues, having discovered subsequently that it is connected with a deficiency in the alpha-oxidation route in the liver.
- the fatty fraction from fish is the main source of the omega 3 fatty acids DHA and EPA in the diet, but it is also the main source of PhA.
- Sources with the highest content in EPA and DHA represent the majority of the intake of DHA and EPA, being associated at the same time with the highest concentrations and intake source of PhA.
- Both DHA and PhA share the same sources, far beyond products for food and pharmaceutical use, thus finding the highest concentrations of DHA and PhA in products of marine and microbial origin.
- PhA is found together with EPA and DHA.
- Bacteria, fungus and micro-algae are the organisms in nature with the highest concentration of PhA. Oils derived from micro-organisms with a rich content in DHA and the least proportion of PhA, frequently exceed 100 ug/g.
- DHA from the diet is 100% of animal origin, since there is no DHA in vegetal food sources (except for some algae which are not used as foods). Therefore, the need in vegetarians is much higher, particularly in strict vegans, where the lowest levels can be found. Its deficiency is even greater and considered by some authors as a marker, in the disease Retinitis Pigmentosa (RP) as well as in metabolic neurodegenerative diseases associated with peroxisomal defects.
- RP Retinitis Pigmentosa
- PhA is a risk factor for public health since it induces cancer in prostate, breast, colon... as well as neurological and visual disorders (Lloyd-MD et al., 2008; Allen-NE et al., 2008; Thornburg-G et al., 2006; Xu-J et al., 2005). In addition, it is cytotoxic ( Komen-JC et al., 2007; Sch ⁇ nfeld et Reiser, 2006; Schonfeld et al., 2006, Heinz, 2005; Elmazar & Nau, 2004).
- PhA The intake of PhA is a risk factor for the development and/or evolution of diseases: ophthalmologic (retina, cataracts, dry eye%), olphative and auditive alterations, neurologic (Alzheimer, encephalopathy%) and psychiatric alterations, nephrologic alterations, cardiovascular (electrical abnormalities S. Purkinje, alterations of the smooth muscle, ischaemic cardiopathy, atherosclerosis), myopathies and severe amiotrophy, bone alterations, hepatic alterations, alterations of the male and female fertility, chronic autoimmune and inflammatory diseases (Crohn disease, Colitis ulcerosa, LES) and cancer (prostate, colon, breast, kidney, ovary, some types of leukaemia, etc.).
- PhA is one of the molecules with the highest induction of oxidative stress in vivo, it potentiates the theratogenesis and is a great inductor of atherosclerosis and death by cardiac failure.
- PhA is directly toxic to the mitochondria and exhibits a powerful atherogenic activity. PhA has a rotenon type activity in the uncoupling of complex I in the oxidative phosphorylation in the inner mitochondrial membrane, resulting in the subsequent production of oxygen reactive species and the in vivo lipoperoxidation of DHA and other polyunsaturated fatty acids or PUFA (Kahler-S et al., 2005).
- PhA induces Ca +2 mediated apoptosis in the Purkinje cells (Powers-J.M et Al. 1999) and sudden cardiac death in animal models. PhA produces ischaemia, apoptosis of the vascular smooth muscle, is atherogenic and particularly cardiotoxic. A deficiency in the sterol-2 transport protein (SPC-2) produces sudden cardiac death by accumulation of PhA in mice. PhA induces apoptosis in cell cultures of vascular smooth muscle cells (VSMC) in humans, mice and pigs.
- VSMC vascular smooth muscle cells
- PhA is directly toxic to the cilliary gangliff cells affecting parasympatic gangliff nerves in the posterior region of the ocular orbit, responsible for pupil contraction and for the vision accommodation (presbyopia, hypermetropy, photosensibiity, etc).
- PhA interferes with the function of ciiiiary ceils, basal body and proteins linked to microtubules required for the biogenesis of the cillium, mediated by the interaction of the different types of myosin and prenilation of Rab GTPases in the primary cillium of photoreceptors, affecting the transport of essential proteins such as opsine, olphatory cells, cochlea, renal cells, respiratory system, sperm, intestinal microvilli, as well as to the movement of melanosomes in the pigmentary epithelium in retina.
- RP which exhibits alterations in the metabolism of PhA, is a model of the alteration of cilliary cells, finding abnormalities of the sperm axonema and of the rods cilliary cells, affecting to the renewal of the outer segments of the rods which depend on the cilliary body, resulting in irreversible visual damage.
- alterations of the auditive evocated potentials and alterations of the audiometry compatible with cochlear alterations characteristic of cilliary cells are found. Significative alterations of the cilliary body result in RP and deafness in a way which is comparable to Usher and other syndromes such as in patients non associated to syndromes with auditive alterations.
- Rho and Rab family small G-proteins require addition of these isoprenyl moieties at their C termini for normal GTPase function.
- Rho GTPase signalling pathway are critically needed to target for therapeutic intervention in nephrological diseases, neurological disorders
- PhA and other isoprenoids impaired Rho-GTPase signalling, particularly Rac pathway, in an opposite way to DHA and statins.
- the PhA alters Rho-GTPases in a way comparable to some bacterial toxins in the epithelium and digestive and respiratory mucosa to develop the invasive and infectious processes; tumoral processes and metastasis (ie. prostate, breast), renal lesions
- PhA and PA are controllers of the main and most powerful mediators of the angiogenesis and inflammation phenotypes.
- TNFalpha, GBP-1 , GBP-2 and inflammatory cytokines (Cl) by PhA and PA is a determining factor for the development of cancer (metastasis), autoimmune diseases, inflammatory diseases, infectious diseases, renal, pulmonary and neurological.
- PhA becomes PA by oxidation and both PhA and PA, induce apoptosis mediated by the formation of UNAM of the nitric oxide synthase and high concentrations of the protein within 2 hours from the treatment (Idel et al., 2002).
- PhA and PA control the main and most powerful mediators of the angiogenesis phenotype and the inflammation.
- PhA and PA are the most powerful inducers of the activation and secretion of the tumor necrosis factor ⁇ (TNFcc) (Idel et al., 2002).
- TNFcc tumor necrosis factor ⁇
- the expression of the human guanylate-binding protein (GBP)-I is highly induced by inflammatory cytokines (ICs) and therefore, may characterise IC-activated cells.
- GBP-1 is a novel cellular activation marker that characterises the IC-activated phenotype of endothelial cells.
- GBP-1 is a major regulator of the anti-angiogenic response of endothelial cells to ICs.
- GBP-1 is a cytoplasmic protein and its expression in endothelial cells is selectively induced by interferon-gamma, interleukin-1 alpha, interleukin-1 beta, or TNF-alpha, but not by other cytokines, chemokines, or growth factors.
- PhA and PA are inducers of alpha TNF and of interferon gamma.
- GBP-1 expression is highly associated with vascular endothelial cells but was undetectable in the skin, but it was highly induced in vessels of skin diseases with a high- inflammatory component including psoriasis, adverse drug reactions, and Kaposi's sarcoma. It has been shown that the expression of GBP-1 and of the matrix metalloproteinase-1 (MMP-1) is inversely related in vitro and in vivo, and that GBP-1 selectively inhibits the expression of MMP- 1 in endothelial cells, but not the expression of other proteases.
- MMP-1 matrix metalloproteinase-1
- PhA potentiates the theratogenic effects of retinoic acid (Elmazar & Nau, 2004), being particularly relevant, since DHA, which is frequently associated with PhA, is recommended during pregnancy, nursing and in children food.
- PhA Retinosis pigmentaria
- RP Retinosis pigmentaria
- the physicochemical properties of PhA makes it into an important competitor of DHA when becoming incorporated into the position 2 of phospholipids (the usual position of DHA in photoreceptors).
- PhA has a high number of free rotating bonds (14) and has a very low crystallisation point, enabling a high fluidity in the membrane.
- PhA is lacking the structural conformation characteristic to DHA for the Van der Waals interactions, with the alpha-helix of rhodopsin, necessary for its mobility in the membrane and the tertiary structure.
- PhA reduces the activity of rhodopsin and of the phototransduction.
- PhA has the ability to uncouple the photoreceptors membranes resulting in a failure in the phototransduction (continuous hyperpolarisation) found in RP.
- PhA is not sensitive to the degradation by oxidation and is resistant to dystrophic conditions such as those found in RP. This happens especially in cases of DHA deficiency, such as in RP, consequence of the dystrophy, where it is the single disease where there is a deficiency in DHA, being considered as a marker of the disease.
- PhA modifies the function of photoreceptors through its incorporation to the phospholipids and triglycerides, displacing DHA (McCoII & Converse, 1995; Powers et al., 1999, M ⁇ nning et al., 2004) and reducing the levels of DHA due to the lipoperoxidation and mitochondrial damage induced by PhA.
- PhA also has the toxic ability to act as a protons transporter (uncoupling agent) not only in mitochondria but in the photoreceptors membranes (Gutknecht-J, 1988), thus altering the polarisation of the outer segments of the photoreceptors. Displacement of DHA by PhA.
- PhA modifies the function of the photoreceptors through its incorporation into the phospholipids and triglycerides, thus displacing DHA from the second carbon of the phospholipids in the ROS membranes and the mitochondria. Therefore, the displacement of DHA from the membranes by PhA alters the function of the photoreceptors, behaving as a DHA antagonist in the phototransduction, altering the calcium homeostasis and the regeneration of rhodopsin.
- PhA is one of the most powerful inductors of oxidation and apoptosis in vivo, interfering on an antagonist manner with the action mechanisms of DHA. PhA levels in the oil interfere with the activity of DHA 1 since capacity of DHA to inhibit apoptosis in retina is reduced by the presence of PhA on a dose dependent manner.
- PhA produces apoptosis in photoreceptors in animal models with RP producing an irreversible damage in mitochondria. Under these conditions, the peptides responsible for the survival of photoreceptors are incapable of inhibiting apoptosis.
- DHA is the single fatty acid that neutralises the reactive species in retina under dystrophic conditions. PhA is particularly toxic in dystrophic retinas and DHA reduces its effects. It has been proved that DHA is an inhibitor of oxidative stress and the irreversible mitochondrial damage which causes photoreceptors degeneration (Rotstein et al. 2003).
- PhA besides being cytotoxic, is an antagonist of DHA with all the implications involved. Specifically, PhA on an antagonist manner to DHA, induces apoptosis via mitochondria.
- PhA is essential for the survival of several tumor cell lines (prostate, kidney, breast, colon, lung) resulting in the over-expression of AMACAR and SPC-2. Cases have been described with deficiencies in AMACAR with neuropathy, RP and an increase in PhA and PA (Ferdinanduse et al., 2000).
- PhA More than 50 mg/day of PhA are eliminated via oxidation and cytochrome P450. It is well known that the oxidation of PhA is mediated by cytochrome p450, but it is also known that that there are strong inhibitors of cytochrome P450 (ie. antimicotic azolics, valproic acid, cimetidine, erithromicine, Sulfametoxazol, opioids, cyclosporine, protease inhibitors, antidepressants, hyperphorine, barbiturics, antihistaminics, tamoxifen, cannabioids, S- warfarine, etc.). Thus, certain drugs can increase PhA concentrations on a significant manner.
- cytochrome P450 ie. antimicotic azolics, valproic acid, cimetidine, erithromicine, Sulfametoxazol, opioids, cyclosporine, protease inhibitors, antidepressants,
- PhA can interact with calcium antagonists, antiangiogenic agents, immunosuppressors and antiinflammatories.
- the fast oxidation of PhA (alpha-oxidation 90% oxidation of PhA) in the human body is mediated by different isoenzymes of cytochrome P450 (ie. CYP2C8).
- cytochrome P450 ie. CYP2C8
- One the most outstanding drugs, due to its commercial interest and use are the hypolipemiant drugs: fibrates and statins, inhibitors of P450 CYP2C8 which strongly inhibit the oxidative metabolism of PhA, resulting in an accumulation of PhA.
- PhA Fibrates activate the ⁇ -oxidation in peroxisomes, but the degradation of PhA needs the alpha-oxidation which is inhibited by fibrates through the inhibition of cytochrome P450 CYP2C8. PhA is likely to be partly responsible for its main secondary effect: rhabdomyolysis.
- Nutritional alterations antioxidants: thiaminases and thiamin antagonists, acetylcholine
- thiaminases and thiamin antagonists that affect the decrease in thiamin, where thiamin pyrophosphate is a cofactor in the oxidation of PhA (via ligases), as well as thiamin deficiencies from which the most well known are those related to the Wernicke-Korsakoff syndrome, the fatal cardiovascular disease beriberi and the neurotoxic syndrome due to consumption of carp and salmonids.
- Thiamin antagonists are found in substances such as food preservatives (ie. sulphites) from plants and frequent foods (ie.
- Alcohol and pyrithiamin (thiamin antimetabolite) oniy require 100 ⁇ g/ml in order to produce a severe deficiency of thiamin in less than 7 days. These interactions bring to the attention that it is not only important to assess the amount of PhA and phytol contained in food, but that foods associated to the diet, pharmacological treatments, food supplements and habits, can affect the accumulation of PhA from the diet.
- PhA is one of the molecules with the strongest capacity to induce oxidation in vivo, interacting with some essential physiological mechanisms of DHA and reducing its levels in vivo, damaging its structure through lipoperoxidation.
- blood concentrations 300 ⁇ g/ml or ⁇ 1 mmol/l ( ⁇ 1% total fatty aids) and approx. 5-10% of the total fatty acids of the nervous tissue it creates a severe neuropathy and death.
- PhA PhA
- Refsum's disease both in adults and children with a severe accumulation of PhA is an ideal model to study the toxicity by PhA which includes retinosis pigmentosa, nistagmus, hypotony, ataxy, mental and growth retardation, facial and bone dysmorphies, hepatomegaly and hypocholesterolemia.
- PhA toxicity is related with diseases and situations where the intake of DHA is recommended and used, such as in retinosis pigmentosa (RP), where DHA behaves as a marker of the disease and PhA is the etiological agent of RP.
- Diseases which commonly require DHA for their treatment are induced at the same time by PhA. Besides the oncologic ones, the most evident one of all is RP.
- the branch chain fatty acids PhA and PA are markers in different RP diseases (Refsum, Neonatal Adrenoleukodistrophy (NALD), Chondrodysplasia punctata rhizomelic, Zellweger, Usher IV) associated with a defect in the metabolism of the alpha- and beta-oxidation of PA. PhA is the single cause of RP in these cases.
- PhA is found in the human diet or in animal tissues where it can derive from chlorophyll from plant extracts; this is how it can accumulate in animal tissues. PhA is formed from phytol and is oxidised forming pristanic acid (PA). Given the important variations that exist in the fatty diet of the population (vegetarians, ovolactovegetarians,...), variations in PhA blood levels have been found (up to 6.7 times) exclusively related with the consumption of PhA from the conventional diet, where vegetarian diets exhibit up to 10 times less PhA whilst at the same time are extremely deficient in DHA.
- PA pristanic acid
- DHA Whilst phytanic acid is a risk factor for prostate cancer, DHA is a protective factor for the same type of cancer. Evidence exceeds to the numerous molecular studies and is supported by epidemiological data and numerous pharmacologic studies, some of which are well advanced (Phase II), regarding the role of DHA in combination with other chemotherapeutical drugs (celecoxib, Plaquitaxel) in the prevention and first line treatment of prostate cancer as well as gastric cancer (Ballet et al., 2004; Jones et al., 2007).
- chemotherapeutical drugs celecoxib, Plaquitaxel
- EPA and DHA which comprises: (a) add to the oil an aliphatic alcohol of C1-C4, preferably ethanol in an aqueous solution at 60-70%, at a temperature to which the oil and alcohol separate into two phases (round about 1O 0 C); (b) heating the mixture until the oil and the alcohol become miscible (50-80 0 C): (c) cooling down the mixture at a temperature in which the oil and alcohol separate (approx. 1O 0 C); and (d) recovery of the oil phase.
- document ES 2035751 T3 which refers to a procedure to prepare a triglyceride which has at least one long fatty acid C8+ in the molecule, characterised by an interesterification, in the presence of a lipase, the free long chain fatty acid or one of its inferior alkyl esters C1-C4 with a triglyceride which has one or more short chain fatty acids C2-C6 in the molecule and separate by evaporation during the reaction, the short chain free fatty acid or its inferior alkyl ester, and composition in which the polyunsaturated acid is EPA or DHA or a mixture of both.
- Document GB 2350610 A describes the preparation of DHA from this oil as a triglyceride through a procedure that uses a combination of a transesterification of the triglycerides with an inferior alkylic alcohol, distillation and a selective enzymatic transesterification with an alcoxy alcohol catalysed by lipases that can be immobilised.
- document US2008/0114181 A1 refers to a method for the esterification of fatty acids into triglycerides with aliphatic alcohols C1-C8.
- the method uses an acidic ion exchange resin as a catalyser, which comes into contact with the mixture of the reaction which contains a triglyceride that at least has 1% of free fatty acids and an aliphatic alcohol C1-C8, in adequate conditions for the esterification.
- Document ES 2056852 T3 also claims a procedure for the extraction of the ethylic ester of DHA from fish oil, which includes the transesterification of the fish oil with ethanol in presence of sulphuric acid, followed by the extraction of the mixture with hexane, silica gel chromatography, treatment of the residue in acetone cooled down to -4O 0 C, filtration, evaporation of the acetone and molecular distillation in two steps at 0,133 Pa, the first step at 80-100 0 C and the second at 105-125 0 C.
- 1557453 (A) which describes a composition to increase memory and improve knowledge which comprises the serrate herb clubmoss, rhodiola root and a fish oil concentrate with 50 mg de
- DHA as an active substance. It specifies that it strengthens the transmission of the information between neuronal synaptic connections, improving the resistance to anoxia, stabilising the structure of the nervous cells and supplying such nerve cells with essential nutritive material.
- DHA has been mentioned in different documents as having beneficial properties for health, for example, as a nutritive substance for the human brain and to revitalise the intelligence (CN 1130040 (A)).
- JP 8098659 (A) it is mentioned that DHA, as an ester or phospholipid, has an improved effect against stress.
- CN 1105205 (A) gives a description of a capsule which contains 11-45% of pure DHA together with calcium, vitamins and starch, to tonify the brain and activate the intelligence.
- document ES 2277557 A1 refers to the use of DHA for the manufacture of a pharmaceutical composition geared towards the treatment of the oxidative cellular damage.
- document EP 1065196 A1 refers to a process to selectively separate and purify
- EPA or DHA or their esters from a mixture of acids or esters which comprises: (a) passing an aqueous fluid with a silver salt through a column with diatom earth, so that the silver salt adheres to the diatom earth; (b) pass through the column with diatom earth and silver salt, a solution with solvents of a mixture containing the fatty acids highly unsaturated or its derivates; and (c) passing a solvent to separate the desired fatty acids.
- Document US 6,846,942 B2 refers to a method for the preparation of pure EPA and DHA which comprises: a) dissolving the mixture of DHA and EPA in acetone and adding magnesium ions, which produces EPA and DHA salts which have different solubility in acetone, b) cool down the solution obtained in (a) to precipitate the EPA salt, c) filter the precipitated EPA salt, and d) acidify the precipitate obtained to obtain pure EPA, and e) evaporate the solvent from the filtrate to obtain pure DHA.
- the EPA and DHA mixture is obtained from a fish oil, this is firstly subjected to an alcoholysis or saponification in order to transform the triglycerides into free acids.
- compositions that should not only be beneficial for the diet and health due to the presence of DHA in effective amounts for health, that is, in high amounts of DHA, but at the same time it should contain the least possible amount of PhA in order to prevent its effects when taking in DHA.
- a first object of the present invention a process to obtain a composition rich in omega 3 fatty acids from an oil of marine origin, with PhA levels below 90 ⁇ g/g, wherein the mentioned procedure comprises the following steps:
- an oil of marine origin is saponified in order to obtain fatty acids salts.
- step b) the fatty acid salts from step a) are acidified in order to obtain acidified oil.
- step c) the acidified oil from step b) is subjected to ultracentrifugation in a glycerol gradient at a temperature of 1O 0 C under vacuum (27Pa).
- step d) the glycerol gradient from step c) is subjected to crystallisation to a temperature range between 0 and -57 0 C obtaining a solid phase and a liquid phase, where the solid phase contains saturated fatty acids, monounsaturated fatty acids and PhA and the iiquid phase contains polyunsaturated omega 3 fatty acids with a PhA content below 90 ⁇ g/g
- step e) the liquid phase from step d) is separated from the solid phase for its recovery through decantation.
- the procedure comprises a further step in which the omega 3 fatty acids are esterified to obtain omega 3 triglycerides with a PhA content below 90 ⁇ g/g.
- the saponification step a of the present object of the invention is carried out in a preferred embodiment with KOH, water and ethanol, shaking the mixture at a temperature of 4O 0 C at 300rpm during 1 hour in a inert atmosphere.
- the acidification step b) is carried out mixing the fatty acid salts obtained in step (a) with acetic acid at 70% in an inert atmosphere at 200 rpm.
- step c If the ultracentrifugation of step c is isopicnic, this implies that the centrifugation conditions used should be 10000Og during 42 hours. If the ultracentrifugation is according to density gradient without equilibrium, then the centrifugation conditions should be 10000Og during 24 hours.
- the ultracentrifugation step is isopicnic
- the cristallisation step is carried out at a temperature of O 0 C.
- the ultracentrifugation step is isopicnic
- the cristallisation step is carried out at a temperature of -3O 0 C
- the ultracentrifugation step is in density gradient without equilibrium, the cristallisation step is carried out at a temperature of-30°C
- a second object of invention comprises a composition, obtained following the procedure described in the first invention, of omega 3 fatty acids in a range of 65% to 99% in weight, with a
- PhA content below 90 ⁇ g/g preferably with a content in omega 3 fatty acids in a range of 75% to 99% in weight, more preferably where the omega 3 fatty acids represent at least 90% of the weight.
- the composition obtained according to the procedure described in the first invention, comprises omega 3 fatty acids in a range of 65% to 99% in weight, with a PhA content below 5 ⁇ g/g, preferably with a content in omega 3 fatty acids in a range of 75% to 99% in weight, more preferably where the omega 3 fatty acids account for at least 90% of the weight.
- the omega 3 fatty acids comprise DHA at a range between 65% to 95% in weight, with a PhA content below 90 ⁇ g/g, preferably with a DHA content of 75% to 95% in weight, more preferably with a DHA content of at least 80% in weight.
- the omega 3 fatty acids comprise DHA at a range of 65% to 95% in weight with a PhA content below 5 ⁇ g/g de PhA, preferably with a DHA content of 75% to 95% in weight, more preferably with a DHA content of at least 80% weight.
- the omega 3 fatty acids composition obtained, according to the procedure described in the first invention additionally comprise EPA in a range of 5 to 35 % in weight.
- omega 3 fatty acids comprising DHA composition obtained, according to the procedure described in the first invention additionally comprises EPA in a range of 5 to 35 % in weight.
- the percentage in weight of DHA is of 80,65% and the percentage in weight of EPA is of 13,38%, being the percentage in total weight of fatty acids in the mentioned composition of 91 ,75%.
- composition obtained according to the procedure described in the first invention additionally comprises cofactors, extracts and/or active substances for pharmaceutical or alimentary use.
- composition obtained according to the procedure described in the first invention additionally comprises excipients and/or adyuvants intended for pharmaceutical or alimentary use.
- a third object of invention refers to a nutritional supplement which comprises the compositions described in the second object of the invention on a drinkable format, soft or hard gels, aqueous emulsion or powder.
- a fourth object of invention refers to a food product which comprises the compositions described in the second object of invention on a drinkable format, soft or hard gels, aqueous emulsion or powder.
- a fifth object of the invention relates to a pharmaceutical composition which comprises a compound rich in omega 3 fatty acids according to the second object of the invention or as obtainable by a method according to the first object of the invention or a pharmaceutically diluent or carrier.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of allergic condition, eye surface diseases and dry eye preferably selected from the group consisting of blepharitis, blepharoconjunctivitis, conjunctivitis, keratitis, dry keratoconjunctivitis, corneal diseases, treatment against corneal transplant rejection, increase of the average cellular corneal density through pachymetry in pre- and post-Lasik surgery.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of retina degenerative diseases non associated with genetic dystrophies, preferably selected from the group consisting of humid or dry macular degeneration associated to age degeneration, diabetic retinopathy, glaucoma, intraocular pressure alterations, retinopathy associated to myopia, retinal detachment, rhegmatogenous retinal detachment in myopic eyes after LASIK, secondary macular oedema of ischaemic origin, cystoid macular oedema or Irvine- Gass syndrome, Berlin Scotome, Choroidosis, Chorioretinitis, Syphilitic Neuroretinitis, Rubeola, Cytomegalovirus, Malign melanoma of coroids, mercury poisons (Minamata disease, Acrodynia, Hunter-Russell syndrome), Retinal vasculitis (Eales' disease), haemorrh
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of hereditary retina dystrophies non retinitis pigmentosa preferably selected from the group consisting of Stargardt disease, X-linked Choroideremia, Leber's congenital amaurosis, X-linked retinoschisis, Goldman-Favre viteoretinal dystrophy. Wagner's vitreoretinal dystrophy, and Stickler's syndrome, Familial Pars Planitis.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of Retinosis Pigmentosa.
- a ninth object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of Retinosis Pigmentosa related syndromes.
- the treated retinal dystrophies are non syndromic RP with as a result of specific mutations and/or failure in the hepatic synthesis or transport of DHA or as consequence of metabolic stress and are preferably selected from the group consisting of all Mendelian types of typical non systemic RP such as sectorial, bilateral, unilateral, bilateral, inverse; autosomic dominant RP; autosomic recessive RP; linked to X RP; simple or sporadic RP; vitreoretinal RP; RP punctata albescens; RP without pigment; choroideal atrophy; choroidea girata and/or retinal athrophy; RP with dystrophy of cones and rods;, Usher syndrome such as type I, II, III, IV; iatrogenic RP such as NP 207, Thioridazina, CloroKine, HidroxycloroKine, Clorpromacine.
- typical non systemic RP such as sectori
- the treated retinal dystrophies are genetic syndromes with peroxisomal defects with RP and/or deficiencies in DHA and increases in PhA and PA that exhibit variable neurologic, cardiovascular, musculoskeletal and dermatologic alterations and are preferably selected from the group comprising: Zellweger syndrome, Infantile Refsum disease, neonatal adrenoleukodystrophy, peroxisomal biogenesis disorder, rhizomelic chondrodysplasia punctata (RCDP), acyl-CoA oxidase deficiencies, bifunctional enzyme deficiencies, Refsum disease, ⁇ -oxidation deficiency, Familial ichthyosiform keratoderma (Sjogren-Larsson Sindrome). Diseases with mitochondriopathies (Complex IV): COX deficiency,
- the treated retinal dystrophies are genetic syndromes with peroxisomal, mitochondrial defects and/or related with RP and related retinal alterations and are preferably selected from the group comprising S. Bassen-kornzweig, S. Batten or lipofuscinosis, hipoprebetalipoproteinemia, S. Usher, S. Hallervorden-Spatz, Aceruloplasminemia, S. Kearns-Sayre, Duchenne and Becker muscular distrophy, S. Lawrence- Moon-Bardet-Biedl, S. Lawrence-Moon, S Bardet-Biedl, S. Grafe, Leber's congenital amaurosis, S. Hallgreen, S. Cokayne, S.
- renal-ocular- skeletic S Edwards, S. Oculocerebrorenal linked to X recessive or S. Lowe, Lignac-Fanconi syndrome (cystinosis), Ggan axonal neuropathy, Familiar Danish Dementia etc..
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of uveitis and diseases related, preferably selected from the group consisting of crizis; Pars planitis; choroiditis; chorioretinitis; anterior and/or posterior uveitis; iridocyclochoroiditis; infectious uveitis such as Brucellosis, Herpes simplex, Herpes zoster, Leptospirosis, Lyme disease, presumed ocular hystoplasmosis syndrome, syphilis, Toxocariasis, Toxoplasmosis, Tuberculosis, Candidiasis; uveitis syndromes such as acute posterior multifocal placoid pigment epitheliopathy, Birdshot retinochoroidopathy, Fuchs heterochromic iridocyclitis, Multifocal Choroiditis and Panuveitis Syndrome, multiple evan
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of retina degenerative disease and propely ophthalmological conditions related with vascular diseases preferably selected from the group consisting of hypertensive retinopathy; Hypertensive optic ischaemi neuropathy; Hypertensive Choroidopaties such as choroideal sclerosis, branch or central vein thrombosis, Elschnig and Slegrist streaks; atherosclerosis; cerebral and neuro-ophtalmologic ischaemia; aortic arch syndrome; Takayasu disease; Takayasu arteritis; Panarteritis; iridocyclitis; scleritis; preretinal neovascularisation produced by ischaemia and that can result in vitreous haemorrhages; corneal oedema;, Tyndall in aqueous humor; proliferative diabetic retinopahty or ne
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of loss of visual acuity non associated to retinal and other ophthalmologic uses preferably selected from the group consisting of cataract, vitritis, vitreous detachment, endophthalmitis, hipermetropy, myopia, and/or presbyopia.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of neurological and/or psychiatric disorders particularly neurodegenerative preferably selected from the group consisting of hereditary motor sensory neuropathies, ataxy, spasticity, neuritis, Alzheimer disease, dementia, primary attention deficit, depression, bipolar and schizotypic disorders, multiple sclerosis and/or lateral amyotrophic sclerosis.
- neurodegenerative preferably selected from the group consisting of hereditary motor sensory neuropathies, ataxy, spasticity, neuritis, Alzheimer disease, dementia, primary attention deficit, depression, bipolar and schizotypic disorders, multiple sclerosis and/or lateral amyotrophic sclerosis.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of oncologic diseases preferably selected from the group consisting of metastasis and the most prevalent tumoral lines, colorectal cancer, prostate cancer, breast cancer, lung cancer, ovary cancer, gastric cancer, esofagic cancer, pancreas cancer, renal cancer, hepatocarcinoma, brain cancer, glioblastoma, melanoma, retinoblastoma, gall baldder, multiple myeloma, endocrine cancers and/or cancers related with a resistance to insulin.
- oncologic diseases preferably selected from the group consisting of metastasis and the most prevalent tumoral lines, colorectal cancer, prostate cancer, breast cancer, lung cancer, ovary cancer, gastric cancer, esofagic cancer, pancreas cancer, renal cancer, hepatocarcinoma, brain cancer, glioblastoma
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of de nephropathies (nephritis and nephrosis) preferably selected from the group consisting of nephropathies by IgA, nephropathy associated to Systemic Lupus Eritematous, renal insufficiency, glomerulopathy, tubulopathy, interstitium and/or renal vascular disease.,
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of cardiovascular diseases, preferably selected from the group consisting of ischaemic alterations, artheriosclerosis, hypertriglyceridemia, hyperlipemias, ventricular arrhythmias, hypertension, diabetes and/or cardiovascular diseases wherein the Apoprotein a (apo (a)) levels are increased.
- cardiovascular diseases preferably selected from the group consisting of ischaemic alterations, artheriosclerosis, hypertriglyceridemia, hyperlipemias, ventricular arrhythmias, hypertension, diabetes and/or cardiovascular diseases wherein the Apoprotein a (apo (a)) levels are increased.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of iatrogenies preferably selected from the group consisting of rhabdomyolysis, hepatotoxicity, cardiotoxicity, neurotoxicity, oedema, lipodistrophy, and/or immunosuppression, associated to statins, corticoids, antiretrovirals and/or immunosuppressors.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of autoimmune diseases, chronic inflammatory and skeleton muscular diseases preferably selected form the group consisting of rheumatoid arthritis, juvenile arthritis, Sjogren disease, ankylosing spondylitis, systemic lupus eritematous, arthrosis, osteoporosis.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of dermatologic diseases, preferably selected from the group consisting of androgenic alopecia, acne rosacea, acne vulgaris, eczemas and/or psoriasis
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of allergic conditions, asthma and/or chronic respiratory diseases.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of digestive system diseases and inflammatory bowel diseases preferably selected form the group consisting of autoimmune, viral and/or toxic, gastritis, esophagitis, Crohn's disease, ulcerative colitis, pseudomembranose colitis, colagenous colitis, alterations of the intestinal permeability, malabsorption syndromes, food intolerance and allergies and/or haemorroids
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of parasitic and infectious diseases.
- Another object of the invention relates to the use of a compound according to the second object of the invention for manufacturing a pharmaceutical composition for the treatment or prevention of deficit of DHA.
- deficit is due to gastrointestinal malabsorption syndromes selected from the group comprising cystic fibrosis, intestinal malabsorption syndromes, pancreatitis, pancreatic insufficiency and/or cholelithiasis.
- the DHA deficit is due to alimentary disorders selected from the group comprising anorexy and/or bulimy.
- the compound of this object of invention relates to compensate the common nutritional DHA deficiency observed in human societies, preferably in the group comprising pregnant women, nursing women and childhood preferably during the first year of life.
- Another object of the invention relates to the use of a compound according to the second object of the invention as a cofactor or coadyuvant with other medicines to reduce its secondary effects and/or increase its therapeutic activity when associated with: statins, anti-inflammatory drugs, corticoids, immune supressors, antihypertensive drugs; treatment as hypolipemiant, antiinflammatory, autoimmune diseases, allergies, treatment against the rejection of transplanted organs and/or antihypertensives.
- Another object of the invention relates to the use of a compound according to the second object of the invention to improve physiological conditions increasing the visual acuity, memory and cognitive functions, increasing the sports performance and reducing lesions and/or reducing the normal neuromuscular fatigue.
- FIG. 1 Capacity of inhibition of photoreceptors apoptosis (%) by DHA induced by Paraquat in vitro at different concentrations of PhA (blue) and Bcl-2/Bax index (green). The red line shows the degree of apoptosis without treatment with DHA.
- DHA oils ⁇ 5 ⁇ g/g of PhA have a greater inhibitory activity of apoptosis than those with larger concentrations and the oxidative stress produced is also less. This determines that DHA ⁇ 5 ⁇ g/g in vitro, has a higher physiologic activity for the treatment of retinal dystrophies as an inhibitor of apoptosis.
- FIG. 3 This figure represents the main companies and products of the market, as well as those found with the lowest levels of PhA of the market when the study was carried out. Their quality and processes are guaranteed for the majority of manufacturers, fulfilling alimentary and pharmaceutical GMP's in accordance with the European Pharmacopoeia and the FDA, being expressly approved for alimentary use. They are the object of patents and are being systematically studied in human research. It can be seen, that the commercial oils at different purities of DHA, contain high levels of PhA and significantly different regardless of the purity of DHA.
- FIG. 4 Reduction of the levels of PhA in patients without syndromes with DHA ⁇ 5 ⁇ g/ml.
- This figure shows the evolution of 11 patients with RP without associated syndromes with DHA containing PhA ⁇ 5 ⁇ g /g previously treated with DHA containing PhA > 5 ⁇ g/g.
- patients with RP who had DHA with levels of PhA >5 ⁇ g/g increased their levels of PhA (TO), showing a significant reduction of the PhA levels when taking DHA with
- PhA ⁇ 5 ⁇ g/g This demonstrates that DHA with PhA ⁇ 5 ⁇ g/g is safe as a treatment in patients with RP.
- the method DSC is a thermo-analytical technique which differentiates the heat needed to increase the temperature of a sample.
- the main functions of the technique are the study of the phase transitions or of the physical state such as the melting point (MP). This technique exhibits a great sensibility to estimate the MP.
- MP melting point
- PhA from tunna has been purified.
- the graph represents the MP from a sample which contained > 96.5% of PhA separated from an oil rich in DHA (>700mg/g) from tuna, following the procedure of this invention.
- a DSC has been carried out and two clearly differentiated peaks have been found. In order to do so, it has been crystallised at -50 0 C and both phases separated which have been analysed by means GC-MS indicating that they were the two fractions of PhA.
- the DSC technique is repeated once more and on a pure way it is seen a single peak at -45 0 C and -65 0 C for each of the phases separated. Through crystallography it is verified and checked that the isomer PhA(3S) has a MP at -45 0 C and PhA(3R) has a MP at -65 0 C.
- the two isomers show different physiopathological activities in human health.
- the determination of the isomers through this analysis would be an epidemiological, clinical and nutritional marker of great significance to determine the activity of other molecular markers such as AMACAR (associated to 3S and not to 3R) in cancer vs the toxicity from predominant (3R).
- AMACAR associated to 3S and not to 3R
- Fractional Crystallization by Density Fractioning in a density equilibrium gradient or isopicnic of a crude oil rich in omega-3. Fraction (a) green colour, fraction (b) blue colour and fraction (c) orange colour.
- the diagram represents the formation of the fatty acid fractions produced when the oil is exposed to an isopicnic centrifugation.
- Omega 3 fatty acids (fraction c) which correspond to the largest density in the oil used in the starting point, become fractioned in the furthest part of the rotor axis, whilst fractions a and b with lower densities and closer to the rotor axis.
- the cristallysation of the gradient and of fractions a and b enable separating the liquid phase, where the omega 3 fatty acids remain in fraction c.
- the present invention relates to a method for obtaining rich omega-3 fatty acids containing phytanic acid in levels lower than 90 ⁇ g per gram of oil.
- the subject invention provides a method for separating process of the omega-3 fatty acids present on marine animals, microorganisms and algae through a temperature gradient, cooling the extracts until forming a solid-phase which concentrates PhA and saturated and monounsaturated fatty acids, and a liquid-phase, which concentrates omega-3 fatty acids, preferably DHA, essentially PhA free.
- the described process can be used for obtaining and purifying any highly unsaturated fatty acids existing in nature.
- omega-3 fatty acids preferably DHA, substantially PhA free
- DHA substantially PhA free
- omega-3 can also be obtained from other marine sources (i.e.: tuna, cod, salmon, sardine, red fish, whale, seal, shark, non- unicellular algae, etc.), bacterial sources and fungus.
- the most valuable sources are those of microbial origin (obtained from controlled cultures and fermenters), which contain higher levels of PhA and isoprenoids, along with marine sources.
- PhA producers Some species not yet used (i.e: Diatomea algae) would raise great interest as PhA producers, as cod liver oil would do as a source of pristane.
- cod liver oil would do as a source of pristane.
- the aim of this phase is the elimination of unsaponifiable fats. It is exclusively applicable to raw primary materials, non-refined, such as raw fish oil.
- the aim of this phase is to allow the process for obtaining free fatty acids from oil.
- Hydrolysis can be: a) saponification + Acidolysis or b) Hydrolysis by lipase
- the saponification process will form fatty acid salts. Acidification will form a phase of non- polar free fatty acids (acidified oil), and a polar phase of salts that will be eliminated opening the base of the reactor.
- the acidified oil obtained in the previous phase is subjected to ultracentrifugation by glycerol gradient in this stage. Centrifugation may be isopycnic or by non-equilibrium density- gradient.
- Temperature can be reduced to -30 ° C for 24 h, using a glycerol gradient, obtaining two phases as a result: a solid phase, containing saturated and monounsaturated fatty acids, PhA and the glycerol gradient; and a liquid phase, containing polyunsaturated fatty acids with 65-99% omega-3 fatty acids levels, with 65-85% DHA levels containing less than 5 ⁇ g/g of PhA.
- centrifugation is non-isopycnic, temperature should be reduced dramatically to -3O 0 C the glycerol gradient, when two fractions are generated: a solid fraction, containing saturated and monounsaturated fatty acids and PhA, and a liquid fraction, containing polyunsaturated fatty acids with 65-99% omega-3 fatty acids levels, with 65-85% DHA levels containing less than 90 ⁇ g/g of PhA.
- the aim is to stabilise free fatty acids as esters and ethyl-esters, or as triglycerides (which would be a first final product)
- PhA is not separated -unless a specific phase is stablished for that aim-, since physicochemical properties of PhA (C20) are comparable to long-chain omega-3 fatty acids (C>18): PF, melting point, saponification value, iodine index, solubility in water and other solvents, polarity to solvents, optical rotation, etc.
- Cooling refining and purification processes under patent are normally used at temperatures over -5 0 C, and in some occasions it has been carried out at temperatures down to
- PhA and PA are part of the triglycerides found in fish oil comparable to omega-3 fatty acids.
- enzymatic hydrolysis processes are frequently used; it is selective esterification that concentrates omega-3 fatty acids and particularly DHA.
- Long time ago it was demonstrated that in all the biology of PhA, it has tendency to position on the 2nd carbon of triglycerides and phospholipids, as found in DHA and other PUFAs; it is also know that PhA and DHA and other omega-3 share the same resistance to saponification and enzymatic hydrolysis.
- Pancreatic lipase hydrolyses short-chain fatty acids faster than long-chain ones, while PhA, PA, DHA EPA acts very slowly, being resistant to lipolysis (Brockerhoff, 1970; Ellingboe & Steinberg, 1972). Such resistance is comparable to that found on DHA and PhA (Nus et al, 2006), due to the comparable stearic effects of PhA, PA, DHA and EPA (Faber, 2004 y Bottino- NR et ai., 1967). What is more, the use of enzymatic processes couid, as other processes do, increase levels of PhA. Processes such as complete hydrolysis and nonspecific lipase are as efficient as saponification and catalysed hydrolysis with solids, without altering PhA levels.
- Figure 3 shows that methods for obtaining substantially pure DHA (>700mg/g) result in variations that are not efficient for the purpose of this invention. Chromatographic methods are probably the best option, and although it is not specific for separating PhA, it is indeed for obtaining substantially pure DHA. A priori, industrial separating methods by chromatography are not sensitive enough to separate PhA and PA at reasonable costs, finding levels out of the required range for this invention, as it occurs in molecular distillation, having the same time, higer risk of having increased levels of benzo(a)pyrene, due to the use of high temperatures. The most outstanding chromatographic methods (i.e.: SFC) are based on polarity and stearic effects.
- Strength absorption depends not only on polarity, washing time and molecular functional group characteristics, but also on stearic factors. As stated before, PhA and DHA have stearic functions, molecular weight, etc. more proximate to DHA than EPA and other fatty acids.
- PhA and PA are not determined.
- GC chromatography techniques
- DHA has been purified from fish oils (specifically from tuna, since it presents the highest concentration levels of
- This invention also implies that it is no longer necessary to purify one or more fatty acids, or to alter the natural composition of oil, for obtaining low PhA oil or PhA-free oil. This is highly relevant when using natural mixtures of omega-3 fatty acids for food or health purposes. This is also a profitable method, since deodorization and purification processes on omega-3 fatty acids are no longer necessary, obtaining a less risky alimentary and pharmaceutical grade than methods being carried out at present.
- the subject invention refers to a specific method for physically separating the PhA found in any oil containing >5 ⁇ gPhA/g and rich in esters of omega-3 fatty acids, for large-scale industrial production of DHA, EPA or other omega-3 fatty acid from sources rich in omega-3, such as fish, algae or other microorganisms with low or zero levels of PhA.
- Such method uses crystallization to obtain a change in the physical state of the oil, keeping PhA and PA in liquid state, since these have MP significantly lower than DHA and omega-3 fatty acids, or any other fatty acid.
- Linoleic acid (C18:2,n6) -8,5 Ethyl-Oleate - 27 0 C
- This invention concerns a highly adaptable method to current technology, particularly to the pharmaceutical and alimentary technologies, since cold technology was already being used in both industries.
- the increase of pressure in oil rich in omega-3 to reduce the MP and its energetic cost are not an option, as PUFAs and DHA are sensitive to hydrogenation.
- this method along with the contemporaneous industrial technology used for separating of PhA, allows an increase of the degree of purity in DHA, EPA and other fatty acids with a very low MP 1 without adding any other additional purification processes. It is also a DHA and omega-3 fatty acids purification process, mainly for fish.
- the subject invention relates to both non-refined and refined oils containing any omega- 3 proportion, and to oils subject to purification for obtaining a high level of purity in any of the omega-3 fatty acids, preferably DHA, or in the total omega-3 content.
- oils for that aim, we can be based on fats or oils containing any kind of ester, principally triglycerides, phospholipids and ethyl-esters.
- the main purpose is to obtain omega-3 oils, preferably with DHA and high level of purity (>700mg/g), low or zero levels of PhA ( ⁇ 5 ⁇ g/g) preferably associated with esters rich in triglycerides to obtain higher purity, stability and bioavailability, with no need to add non- nutritional ingredients with potential interaction grade, such as ethanol, which use as food is avoided, especially among pregnant women and children, whereas this is the population sector where it is more needed and used.
- Free fatty acids are highly unstable to oral use, although its use as an injectable can entail benefits (i.e.: intravitreal injection).
- active principles of this invention are the omega-3 fatty acids, particularly DHA, and taking into account that the required dose is too high for a therapeutic use, we consider triglycerides to be the best option, as it is the ester in DHA which allows higher concentration of the active principle.
- the oral intake of ethyl-esters is damaged, while the natural fatty acids intake on diet comes from triglycerides.
- Daily diet entails a natural intake of more than 100 grams of triglycerides, which demonstrates that DHA is the most efficient intake among mammals from the physiological and pharmacokinetic point of view.
- Ethyl-DHA is a chemical formula hardly used in humans and in nature, whilst that of triglyceride is far more bioavailable and without the drawbacks and secondary effects associated to the ethyl-ester type.
- DHA as ethyl-ester is less efficient, it is physiologically more sensitive to oxidation, it is not a food (it contents alcohol), it does not form part of any diet among living organisms, its use is restricted (not adequate as food), it interferes with other fatty acids and increases the production of other ethyl-esters, interferes with other drugs and foods (i.e.
- PhA is a non-nutritional substance although present on diet, which entails one of the major risks to health.
- This method of separating PhA is a highly effective deodorization method.
- the treatment of fish oil with soil or activated carbon will suffice, with views to eliminate heavy metals, avoiding so any heating or deodorization process.
- the subject invention entails not only the elimination of PhA and PA but also the efficient elimination of the volatile particles which cause the characteristic odour, avoiding also processes that may harm the oil (high temperatures) and reducing costs as no specific processes are added.
- the aforementioned substances will be part of the liquid fraction that is to be separated, and which contains these volatile substances along with the PhA and other alkenes and alcohols with low levels of PhA.
- Deodorization is carried out by cooling process and not by heating, with no need of purification process whatsoever.
- the present invention allows obtaining non-purified refined oils without having to carry out any conventional process for deodorization -which increases the risk of altering polyunsaturated fatty acids (high temperatures).
- PhA is present fundamentally on triglycerides (>80% approx.) and other esters, detected in free form in small amounts, appearing at the same position (C-2) in both triglycerides and phospholipids in oils, the same as PUFA fatty acids and due to their comparable physicochemical characteristics. PhA extraction, as in all processes of purification of DHA and omega-3, cannot be carried out directly from triglycerides, containing 3 fatty acids with different MP according to their mixture.
- fatty acids must be previously obtained by hydrolysis of the triglycerides that are part of the oils or fats in order to form free fatty acids through transesterification (catalytic) to form esters from alcohols o through hydrolysis (catalytic) to obtain the free acids.
- hydrolysis catalytic
- Catalytic Hydrolysis i.e.: saponification + acidification
- Catalytic hydrolysis is a method vastly applied to fish oils taking as a base any conventional method widely developed and used in current industry. Any organic acid of alimentary or pharmaceutical grade would serve as catalysers, such as acetic acid, or solid catalysers such as resins of ionic exchange (styrene resin), or enzymatic catalysis by lipase (ej:
- Fish oils have non-saponifiable fats containing cholesterol, PCBs 1 A and D vitamins, etc., which must be eliminated from oils rich in DHA or in omega-3 with the aim of obtaining an alimentary or pharmaceutical grade.
- a widely used, cost-effective and efficient method to separate non-saponifiable fats (stearin) in refining processes is the complete hydrolysis by saponification of fish oil in moderate alkaline medium, at low temperatures and in an inert ambient to avoid alteration of polyunsaturated fatty acids. In this way, necessary hydrolysis in refining processes is useful to proceed with the separation of PhA in this invention.
- the subject invention was initiated from hydrolysis of triglycerides and esters found in fish oil in a moderate alkaline medium (i.e.: potassium hydroxide of sodium hydroxide) at low temperature, for obtaining a liquid oil and to favour hydrolysis (i.e.: 4O 0 C- 9O 0 C), until the complete hydrolysis and saponification of fatty acids.
- a moderate alkaline medium i.e.: potassium hydroxide of sodium hydroxide
- the resulting mixture contains salts (potassic or sodium) from fatty acids that are not suitable for the procedure described in this invention as it alters the MP in fatty acids, so acidification or catalysed hydrolysis is carried out by use of non-oxidative organic acids (i.e.: acetic acid) adding it to the vigorously stirred mixture for obtaining fatty acids in free form.
- salts potassium or sodium
- Glycerol is safer than solvents of alimentary or pharmaceutical grade, and entails a much easier method given its necessary presence in both the start and the final phase of the product. But the most remarkable aspect is that glycerol allows density gradient separation, which favours crystallization much more efficiently than in fractionation methods currently used with other chemical substances (i.e.: urea), fractioning saturated and monounsaturated fatty acids, and particularly, for separating PhA and omega-3.
- Glycerol in acidified oil is the safest cryoprotectant agent and a good humectant, which favours crystallization of saturated fatty acids in the PhA separation phase.
- the present invention adds glycerol to the acidified oil to favour the density gradient fractionation, which also helps to develop not only the fraction by centrifugation gradient but also crystallization.
- the density gradient centrifugation As for the density gradient centrifugation ussd in this invention, it is required a gradient that gathers certain characteristics: low molecular weight (it reduces centrifugation time), low viscosity, higher density than in solutes (fatty acids), transparent under UV light and good solvent properties.
- Glycerol which has a high density (1.25g/cm 3 ), acts as medium for the density gradient fractionation or molecules split up to 1.15 g/cm 3 as detected in the case of fatty acids found in rich in omega-3 oils. Glycerol can be mixed with water or any other solvent to reduce significantly its eutectic point (i.e: glycerol dissolution at 65% in water reduces the
- Fatty acids composition key in the content of these oils, does not reveal significant differences in molecular weight but in density (three fractions of fatty acids). Its MP behaves similarly, optimising considerably the crystallization of these fatty acids proximate to MP.
- the most adequate one for this invention is the isopycnic one, as it causes fractions according to density because there are no significant differences in the molecular weight between PhA (312.53 g/mol) and DHA (328.5 g/mol) and the EPA (302.4g/mol) required for the zonal technique.
- the density gradient fractionation is carried out before the crystallization in order to form 3 fractions according to the density corresponding to the main oil fractions: saturate and monounsaturated fatty acids and omega-3. This would cause fraction and modification of the eutectic point of the oil's fatty acids mixture, optimizing in a high proportion the solidification of fractions according to their MP. This procedure is also efficient when optimizing in the separation of PhA from omega-3, without using any solvent.
- Fractional crystallization is a process to separate different substances whose solubility is different in terms of temperature variations. Despite the fact that the base of fractional crystallization is referred to this physicochemical property, actually the fractional crystallization consists on the separation of two or more chemical compounds according to their different MP.
- FCD Fractional Crystallization by Density
- the described method could be used for separating components: a) with similar properties (i.e.: homogenous solutions) in relation to complex interactions that result in variations of the eutectic composition diagram, or b) even in heterogeneous compositions with different solubility but where any of the components is highly sensitive to temperature variations or rises.
- the subject invention refers specifically to the separation of a certain oil homogenous composition in two or more compositions, varying their eutectic point and proceeding to temperature variations by applying a cooling process and separating by fractional crystallization.
- the main purpose is to separate a fraction composed of saturated and monounsaturated fatty acids and PhA, which contains a higher eutectic point than a fraction containing omega-3 fatty acids.
- Crystallization and density turn out to be the most differential properties when separating omega-3 fatty acids, PhA and saturated fatty acids.
- This invention allows separating in fractions of fatty acids or micelles (according to the liposolubility of the gradient) containing a high proportion of fatty acids with lower density as saturated an monounsaturated fatty acids and PhA of omega-3 fatty acid, with higher density.
- These two compositions which can be pure or not (mixture of different fatty acids), have different eutectic points in relation to the MP and to the concentration of the individual composition of fatty acids; two fractions of different compositions can be separated by fractional crystallization.
- This process is also particularly efficient for separating even similar substances by fractional crystallization, according to their density.
- This invention when one of the components PhA (3S) in low concentration levels has a similar MP than a (DHA) component/s.
- DHA fractional crystallization
- ultracentrifugation by isopycnic or non-isopycnic density can be applied.
- the application of solvents usually used for obtaining DHA with high levels of purity is not required in the process of this invention.
- Centrifugation has been demonstrated to be 90% more cost-effective in chemical products, 70% in terms of human work load, 60% faster and more ecological because it does not use solvent for separating free fatty acids and fats (Feng et al., 2004). Centrifugation and refrigeration are widely used in the food industry. In this invention it is possible to favour the separation and crystallization of omega-3 fatty acids and PhA with or without solvents. There has been widespread use of ultracentrifugation at a large scale in the pharmaceutical industry. It should be noted that ultracentrifugation allows separating different fatty acid fractions before crystallization.
- centrifugation for the separation of macromolecules is well known, but it has not been used yet for separating very small molecules such as fatty acids with similar molecular weight and different density. It has been separated 99% of DDT, a liposoluble compound with a molecular weight comparable to that of fatty acids, by Ficoll density-gradient ultracentrifugation (Adamich et al., 1974). In this invention, fatty acids with similar molecular weight (with 300 Daltons) are fractionated by isopycnic density-gradient ultracentrifugation.
- Acidified oil containing free fatty acids will be used in the specific phase of this invention: separation of PhA from rich in omega-3 oil.
- the physical state of the oil is changed by crystallization of the oil itself, containing omega-3 fatty acids (i.e.: DHA), keeping PhA and PA in a liquid state and separating specifically the PhA and PA from crystallization of fractions of DHA, EPA, PhA (3S).
- DHA omega-3 fatty acids
- PhA i.e.: PhA
- This technique allows the obtaining of DHA and EPA with high degrees of purity >95% and >99%, or a triglyceride of alimentary or pharmaceutical grade (>850 mg/g), without PhA ( ⁇ 5 ⁇ g/g).
- the costly loss of omega-3 fatty acids can also be avoided.
- Fatty acids have auto-nucleation properties and they do not have the quality of overfusion.
- the melting point (MP) and the freezing point is the same. Because of this, for carrying out the purification of omega-3 fatty acids free of PhA, it would suffice to obtain two or more fractions with different eutectic points that allowed the aforementioned purification process.
- Saturated fatty acids have a high MP (>18°C), whilst in monounsaturated fatty acids the
- MP is >13°C.
- the composition in saturated and monounsaturated fatty acids in raw acidified oil is > 50% (for those of algal origin) and frequently reaches levels of 70% (fish oils).
- omega-3 fatty acids species significantly reduces the eutectic point, which results in an ineffective cooling crystallization process at very low temperatures, such as -2O 0 C.
- deodorization method is optimised, as well as purification of oil containing omega-3 and fractional crystallization of DHA and omega-3.
- fatty acids form a gradient according to their density and not to their molecular weight, due to the fact that they distribute in the reactor during centrifugation.
- the main premise is that the maximum gradient density (i.e.: glycerol) should always exceed the fatty acids density. Centrifugation by density-gradient allows fatty acids to move along the gradient until they reach a point where their density and that of the gradient are the same (isopycnic). In this very moment, crystallization separation will take place, as conventional separation is to be done very carefully and would cause an undesired contamination of the omega-3 oil.
- a gradient containing a partially apolar solvent i.e.: heptanol
- heptanol a partially apolar solvent
- the gradient used for the present invention is glycerol, as it is produced during the process, it is inexpensive and safe for alimentary and pharmaceutical use, without discarding any other gradient for this purpose (i.e.: sucrose), being its high viscosity the biggest inconvenience in both cases.
- sucrose i.e.: sucrose
- solvent mixtures with glycerol are used to reduce viscosity and lower the MP of the gradient. Particularly, is the use of solvents that favour crystallization, but most of all, to reduce the eutectic point and viscosity of the gradient.
- solvents with a high alimentary and pharmaceutical grade such as glycerol/water mixtures, isopropanol or other alcohols, is advisable but not exclusionary.
- Solvents such as glycerol/water mixtures and acetone have a great amphipathic and humectant behaviour as solvents which stimulates the crystallization of the fatty acids, especially at the temperatures required in this invention, as it has a very low MP (-95 0 C).
- the most suitable glycerol mixtures are those that allow glycerol to reduce viscosity, reduce moderately the MP and significantly viscosity.
- the reduction of viscosity of the gradient is essential for the resolution of fractions and the time for equilibrium in order to separate the PhA more efficiently.
- the ideal proportion is that which allows the formation of a supercooled or superfused liquid, decreasing its MP significantly: glycerol: 67% w/w with an MP of -47 0 C.
- the density is reduced, shortening considerably the duration of the centrifugation by density gradient, an inexpensive and safe result.
- glycerol mixtures are also possible, using low amounts of solvent, avoiding a drop of density below DHA (>0.95 g/cm3) so that it can be used as a gradient, acting alcohols as short-chain polar solvents (C1-C5) for the dispersion of micelles, and preferably solvents for obtaining a medium-chain partially polar gradient (C6-C8) that allow the dispersion of free fatty acids.
- the proportion of glycerol in these alcohols must have a higher density and a low MP.
- An amount of glycerol between 5% and 50% allows a reduction of the MP inversely proportional in the range of temperatures during ultracentrifugation, reducing considerably density and viscosity but always being >1g/cm3, necessary for this invention.
- a glycerol gradient at 25% w/w and an MP of approx. -7 0 C allows an optimization of the fractionation procedure reducing the ultracentrifugation time.
- Glycerol at 50% w/w is enough for obtaining a MP of approx. -23 0 C and for exceeding the maximum temperature reduction of an ultracentrifugation at a large scale.
- 3 fractions are formed according to molecular weight and density: a) saturated fatty acids containing mainly myristic, palmitic and stearic acid with a molecular weight of (228-290 g/mol) and a density lower than oil (0.85-0.86 g/cm3 ) b) monounsaturated fatty acids with a similar molecular weight and a slightly higher density (0.88-0.89 g/cm3) c) omega-3 fatty acids with a molecular weight of (300-330g/mol) and a higher density (0.93-0.95 g/cm3).
- the PhA is detected in fraction (b) through an isopycnic centrifugation with a density of (0.88 g/cm3).
- This can be performed with linear or nonlinear, continuous or discontinuous gradients, having chosen for this invention the continuous linear method because of its industrial application. Reducing the time necessary to obtain the equilibrium is essential in this invention.
- the speed of the ultracentrifugation can start at 30,000 rpm or 100,000 x g until equilibrium is reached. There is no excess time in this technique.
- the fatty acids slowly start to diffuse with the help of the gradient.
- the saturated fatty acids crystallize slowly at 2O 0 C and the monounsaturated fatty acids at 1O 0 C.
- the formation of the equilibrium will increase significantly the eutectic point of the oil at the beginning of the ultracentrifugation and with it the slow formation of crystals.
- Fatty acids do not vary significantly in density at a solid state.
- the ultracentrifugation at 1O 0 C contributes to the crystallization of the phases to discard (a) and (b), containing saturated and monounsaturated fatty acids. Therefore, when the equilibrium is reached, it is possible to separate the liquid fraction containing the omega-3 and the gradient without risk of contamination.
- the cooling process can be carried out simply by cooling the beaker containing the gradient in equilibrium.
- this cooling process can take place during ultracentrifugation, as the ultracentrifugates at a large scale allow a reduction of the temperature down to -2O 0 C, improving the crystallization at these stages.
- the cooling process takes place during or close to the equilibrium point, therefore guaranteeing the solidification of the PhA.
- different temperature cycles can be established or a zone fractionation can be used to purify the DHA and EPA.
- Isomer PhA (3S) which can be usually found in small proportions in fish oils and other marine origin oils, with the exception of mammals and microorganisms (i.e.: tuna rich in DHA), has the MP close to DHA (Table 1 and Figure 5).
- This isomer constitutes a big obstacle for its separation by crystallization. Therefore, the separation of this isomer, particularly when using this invention, requires a previous isopycnic centrifugation of the oil, given the differences in the densities of PhA (0.882 g/cm3) and DHA (0.943 g/cm3), while MP temperature of the PhA is just 2°C lower.
- the eutectic point of oils rich in omega-3 is below 4O 0 C before they are fractioned. With this separation procedure it is possible to obtain behaviour of the crystallization of the different fractions differential enough from the different eutectic points of the fatty acid compositions of the fractions.
- the eutectic point of the mixture in fractions (a) a (b) rises significantly, compared to the original composition of the fatty acids, containing PhA (-0.1%). Also contained in this fraction are the volatile components responsible for the characteristic odour of oils.
- the necessary crystallization time can vary between 18 and 72 hours.
- the cooling speed should be slow enough to stimulate the crystallization of fatty acids, although DHA crystallization has occurred in 24 hours with a reduction on temperature/speed of -3.3 0 C or lower cooling speed.
- Crystallization can be done in large deposits, kept in a cold store or cryogenic freezers at a temperature starting at -44 0 C.
- PhA is separated by using a temperature cycle of -3O 0 C (between -2O 0 C and -40 0 C) below the MP of omega-3 fatty acids and the eutectic point of oil. This is how a solid fraction containing saturated fatty acids + monounsaturated fatty acids + PhA can be separated from the liquid fraction containing a high purity of DHA and EPS through filtration, if necessary.
- the glycerol gradient crystallises, staying in liquid state just the fraction with the highest density and lowest MP with a high purity omega-3, also separating the gradient of the omega-3 fatty acids.
- a glycerol/water mixture at 67% w/w it will remain liquid which will allow another centrifugation process by density gradient (i.e.: separation of DHA/EPA or oil rich in DHA/PhA) or to regenerate the gradient for another PhA separation process in another batch of oil. This procedure eliminates almost completely the totality of the two PhA isomers.
- omega-3 oil with high purity in its two principal components DHA and EPA (>95% or >800mg/g) and usually >99% deodorised and with a low or zero PhA. According to the DHA/EPA ratio in the original oil it can be obtained:
- the DHA and EPA can also fractionate the DHA and EPA, obtaining a DHA and EPA of high purity and low content or zero PhA.
- the DHA and EPA present a 10% difference in molecular weight, enough differential for the zonal ultracentrifugation (Arderiu et al., 1988). For this, it is possible to perform a second cooling cycle, a previous and necessary process of zonal density-gradient ultracentrifugation at -5O 0 C or between -44 0 C and -54 0 C, or at any other temperature between the MP of the DHA and EPA. Regardless of the original composition, a high purity of DHA and EPA and a low concentration or no PhA is obtained in all oils.
- alimentary or pharmaceutical lipophylic antioxidant can be added (i.e.: tocopherols) in order to stabilize the oxidation of PUFAs.
- Acidified oil with a low PhA or zero PhA content requires an immediate esterification of the free fatty acids by alcoholysis or formation of novotriglycerides, our main objective, by any conventional mean carried out at the industry at present time, unspecific or selective enzymatic or another method with a liquid or solid catalyst (i.e.: Patent US 20080114181).
- reesterification will be also carried out to obtain triglycerides.
- Raw material 1 Oil containing DHA only without a significant content of omega-3 fatty acids.
- Raw material 2 Oils rich in omega-3 with different DHA/EPA ratios as the only significant content in omega-3 fatty acids.
- DHA/EPA • DHA/EPA ⁇ 1. I.e.: red fish refined oil (30% omega-3) containing triglycerides DHA > 100mg/g; EPA > 150mg/g and PhA > 1900 ⁇ g/g
- Raw material 3 DHA purified oils with a low EPA content > 700mg/g are produced and obtained regularly as ethyl-ether and purified formulations (i.e.: Molecular distillation). They do not require the purification of omega-3 fatty acids, only the PhA has to be extracted.
- Example 1 Procedure to obtain an extract containing triglycerides with DHA > 700mg/g and PhA ⁇ 5 ⁇ g/g, by isopycnic ultracentrifugation and crystallization.
- the raw material used is non-deodorised and non-purified raw tuna oil (Sanco) containing DHA (210mg/g), EPA (67 mg/g) and total omega-3 (285mg/g). After quantifying fatty acids in oil through gas chromatography and mass spectrometrometry, PhA presence was determined (1.3 mg/g). Two decreasing temperature cycles are established for their effectiveness and in order to quickly achieve the main purpose of this innovation of DHA without PhA.
- the tuna acidified oil obtained in the previous phase is centrifuged at 150rpm for 20 minutes forming a solid phase or stearine and a liquid phase containing the free fatty acids which is vacuumed in order to be used in the next step.
- 2400 ml of gradient are prepared from a glycerol/water mixture at 25% w/w, adding 1800 of water and 535ml of glycerol, into which we add the free fatty acids obtained previously and the glycerol at room temperature.
- the mixture is homogenised at 3000 g for 1 h in a Hitachi-Koki CC40 ultracentrifuge and a C40CT4 Core (H) rotor.
- a sample is obtained using a pipette.
- the sample is subject to a GC-MS analysis and subsequently PhA and DHA concentration are checked, which results in ⁇ 90 ⁇ g/mg and 740mg/g, respectively.
- fractions are not separated, even though the could be obtaining a product with PhA concentration below 90 ⁇ g/mg and a DHA concentration of 740mg/g, respectively.
- This liquid fraction contains omega-3 fatty acids rich in DHA with a low or zero PhA content.
- the 281 gr. of fatty acids rich in DHA obtained are analysed by GC-MS. The analysis indicates that in the omega-3 before and after refrigeration at -3O 0 C is 96.7% and 97.2%respectively and PhA levels are below 90 ⁇ g/g before refrigeration and below 5 ⁇ g/g after refrigeration.
- the esterification of the free fatty acids obtained during step 4 we use the method described in the patent US20080114181.
- the styrene resin is mixed at 5% with the free fatty acids (200 g) and glycerol (50 g), introducing a mechanical thermo shaker on the mixture at 185 rpm, 4O 0 C and 20 minutes.
- the reaction is maintained for 24 hours at atmospheric pressure, under an inert atmosphere (nitrogen).
- the mixture is then cooled to room temperature and the resin or catalyst is recovered by filtration of the oil.
- the ethanol is eliminated, obtaining a triglyceride mixture.
- the GC/MS analysis of the oil is determined in order to determine the composition of the triglycerides, partial glycerides and free fatty acids obtained.
- Example 2 Continuous procedure in order to obtain DHA > 700mg/g and PhA ⁇ 90 ⁇ g/g.
- refined red fish (Sebastes sp.) oil was used as a starting raw material.
- (LYSI) with an omega-3 content of 315mg/g, of which 110mg/g are DHA and 165mg/g EPA, and 1.9g/kg PhA.
- the purified oil is divided in two identical portions for PhA separation and purification of omega-3 fatty acids, using one portion for the following step:
- the esterification process used is that described in the phase 5 of the first example.
- a Soxhlet condenser we mix the styrene resin at 5% and the free fatty acids (200 g) and glycerol (50 g) introducing a mechanical thermo shaker on the mixture at 185 rpm, 4O 0 C and 20 minutes.
- the reaction is maintained for 24 hours at atmospheric pressure, under an inert atmosphere (nitrogen).
- the mixture is then cooled to room temperature and the resin or catalyst is recovered by filtration of the oil.
- the ethanol is eliminated, obtaining a triglyceride mixture. From the sample obtained for its analysis by GC-MS we determine that the oil obtained contains less than 0.4% of free fatty acids with a DHA concentration 470 mg/g and PhA ⁇ 90 ⁇ g/g.
- the oil obtained contains less than 0.6% of free fatty acids with a DHA concentration 440 mg/g and PhA ⁇ 90 ⁇ g/g.
- the final product also contains a lower amount of DHA. Even so, we can conclude that from this procedure we have been able to obtain 4 times the DHA quantity (from 110mg/g to 440mg/g) and reduce PhA 200 times. After repeating the process using the obtained product as starting product, a composition with 740 mg/g of DHA and less than 90 ⁇ g/g PhA is obtained.
- GC/MS Chromatographic column HP-1.17mx200 ⁇ mx0.11 ⁇ m.
- Injector temperature 28O 0 C; interphase temperature: 29O 0 C; speed: 5°C/min from 100 0 C to 260 0 C; helium column with flow of 0.9ml/min; sample from the injector: 1 ⁇ l; ionizing source temperature: 23O 0 C; electrode temperature 15O 0 C.
- EXTRACTION In a screw tube add 1 ml of sample, 9.5 ml of chloroform/methanol (2:1) and 2 ml of KCI, shake in a vortex and centrifuge 20 minutes at 3000 rpm. Separate and discard the top layer (aqueous), filter with filter paper on sodium suphate. Recover the filtrate (organic phase) in a tube with a screw top and evaporate.
- DERIVATISATION Add to the dry extract 1 ml of boron trifluoride in methanol, heat at 100 0 C during 30 minutes and cool down the tubes. Add 3 ml of water and 3 ml of n-hexane, shake and leave it to rest. Separate and keep the top layer, add to the aqueous layer 3 ml of n-hexane and shake. Gather the organic phases, filter with filter paper on sodium suphate, evaporate until dry and dilute the sample with n-hexane, inject 2 mcl.
- Example 1 The product obtained in Example 1 was analysed by GC-MS for fatty acids and PhA.
- the total % of omega-3 fatty acids obtained from the analysis is the sum of DHA+EPA+SDA+DPA.
- the composition comprises other omega-3 fatty acids in very low or non-detectable fractions due to the technique, which are not taken into account neither in the pharmacopoeiae nor the analysis (i.e.: C28:8,n3).
- An immunoassay is performed to determine the PCB and related substances as well as the Furan dioxines using a PCB1 and DF1 immunoassay kit from CAPE technologies. For this a simplified method (Harrison and Carlson, 2000) is applied.
- Emulsions with water or another hydrosoluble substance can also be made mixing them with flavour enhancers to be consumed as a drinkable liquid and to prepare liposomes.
- the final product can also be obtained as a powder.
- Other uses different to oral consumption are possible, particularly as intravenous and intravitreal injections as isotonic emulsions, (saline solution).
- the final product of this patent is the development of a supplement and medicament containing 100% liquid oil obtained in the Example 1 in a transparent gelatine soft capsule, size 24 oblong (composition: Gelatine, glycerol, water) containing 1389mg of oil of which IOOOmg are DHA. It is also possible to use capsules with a gastroresistant coating.
- This formula can contain cofactors essential for the treatment of Pigmentary retinosis, such as: Taurine, Beta-alanil-L-zinc histidinate, Lipoic acid, Ester-Ascorbate, Pigments: a) Zeaxantine dipamitate (ES Lycium barbarum), b) delfidinine (ES Vaccinium mirtillus with a low content in cianidine), Myricetine, Naringenine, Hesperitine and their glycosides, Asiaticoside, Ginkgoflavonglycosides A + B; and epigallocatechin gallate, vincamine derivatives. i) cofactors used
- Tetrahydropholate (B9) 100 meg 400 meg
- the different glucosides of this composition i.e.: delphidine and myricetine
- delphidine and myricetine increase the DHA concentration in the retina and photoreceptors and inhibit apoptotic photoreceptors caused by light (Laabich et al., 2007).
- Example 5 Experiments to determine the inhibitor activity of DHA and its mechanisms according to PhA, whether in vivo (oral administration) or in vitro:
- Purified cultures of neurons from Wistar albino rats were prepared according to Politi et al., (1966) and treated in a poli-ornithine medium as in Adler-R (1982).
- DHA 9mM
- PhA / 5/ 20/ 100/ 500/ 2500 and 12500 ⁇ gPhA/g oil
- Anti-apoptotic capacity in photoreceptors of DHA is inversely correlated to PhA concentration (PhA) ( Figure 1).
- the greater anti-apoptotic activity can be obtained by using
- Anti-apoptotic activity in oils with DHA with 0 and 4 ⁇ g/g of PhA is notably higher than in oils with DHA with concentrations of > 20 ⁇ g/g and > 100 ⁇ g/g of PhA, respectively, where the anti-apoptotic activity of DHA is significantly reduced.
- PhA concentrations of 2500mg/g the activity to inhibit apoptosis of photoreceptors is neutralised, and at higher concentrations apoptosis of photoreceptors is induced despite the DHA presence.
- Bcl-2/Bax index besides being inversely correlated to apoptosis of photoreceptors and the oxidative stress, indicates that DHA in concentrations ⁇ 20 ⁇ g/g have significantly less oxidative stress than concentrations > 100 ⁇ g/g.
- Experiment A were used. Instead of using Paraquat for inducing apoptosis, N-Nitroso-N- methylurea (MNU) (Sigma-Alldrich) was used. Instead of analysing cultures in vitro, as in Experiment A, retins from sacrificed Wistar albino rats were analysed. For that purpose, 8 rats S-D with 42 days of age were selected and fed for 4 weeks with a standard basal diet. Each animal was fed in a different way: one rat was on a standard on control diet, while for the other 7 rats this diet was modified with DHA at 15%, having different concentrations of PhA as in Experiment A: 0/4/20/100/500/2500/12500 ⁇ gPhA/g of oil.
- MNU N-Nitroso-N- methylurea
- Example 6 Use of a composition with a high content of DHA and free from PhA for the Clinical study of Retinosis Pigmentosa.
- DHA docosahexaenoic acid
- An intervention randomised cross-over double-blind study was carried out with two groups (A and B) that were treated with an oral dose of 740mg/day (twice the nutritional dose) of drinkable DHA and with less ( ⁇ 0.20mg of PhA) during 10 months, each with a control in the life style habits.
- both groups were crossed over and the same intervention was repeated again in a second phase.
- RP patients have a high incidence of cardiovascular diseases, diabetes and hyperthyroidism. No adverse effects were found. Visual function seems to be more related with the age of onset of the symptoms than with the age of the patient as well as with the concentration of PhA. The dominant type has a better prognosis than the recessive one.
- the sub-group with high levels of PhA has a worse prognosis and shows no improvement in the VA following treatment with 740mg/day of DHA.
- 76.5% of patients improved their VA regardless of the hereditary pattern.
- the treatment did not produce improvements in the visual field. This pilot trial seems to show that DHA could be useful in the treatment of at least the function of the central vision and to determine at which dose the retinal dystrophy could be avoided in RP, bearing in mind that a subgroup of patients showed high levels of PhA.
- Example 7 DHA pharmacokinetic and the effect in peripheral and central visual function in RP and tolerability of DHA at 2 doses: 4g/day (60mg/kg) and 8g/day (120mg/kg) vs. placebo as unique treatment of RP.
- the primary outcome variable was the change in VA average which had increased in 24-months.
- the second outcome variable peripheral visual function
- the DHA-groups showed an electrophysiologic improvement (reduction in amplitude as well as reduction on the EVP latency). No significant clinical differences were present in the
- DHA-group All patients had normal levels of PhA following treatment, except for 1 patient in each DHA- group that had high levels of PhA. Non of the patients had tolerability problems and no adverse effects were observed in the placebo or DHA group. No variations of PhA were observed, except in the two patients with high levels who still had a reduction of 52% and 48% in the 4g and 8g DHA-group respectively. DHA did not produce significant alterations in the AA levels and other omega-6 fatty acids, increasing significantly the concentration of EPA in the
- DHA groups The increase in DHA in target tissues is proportional to the therapeutic dose, where it was observed that DHA levels were 5.2, 7.3 times higher in phospholipids compared to basal levels. Maximum plasmatic concentrations were achieved between 3 h and 6 h after the oral administration with food of a normal fat content.
- DHA is efficient for improving the visual central function in retinal dystrophy, although due to the size of the sample and duration of the trial, it cannot be ruled out benefits in the peripheral visual function of RP patients. It can also be concluded that, DHA is well tolerated as a therapy for RP; the response is clearly dose-dependent.
- Example 8 Determine the efficacy and safety of the composition of the invention in different pathologies associated to retinal hereditary dystrophies.
- retinal dystrophies include a wide group of diseases amongst which the following can be found: Dominant Autosomic Retinosis Pigmentosa (AD), Dominant Recessive Retinosis Pigmentosa (AR), Simple Retinosis Pigmentosa (SP), Retinosis Pigmentosa Linked to Sex (XL), Stargardt Disease (ST), Choroidemia, Leber etc.
- AD Dominant Autosomic Retinosis Pigmentosa
- AR Dominant Recessive Retinosis Pigmentosa
- SP Simple Retinosis Pigmentosa
- XL Retinosis Pigmentosa Linked to Sex
- ST Stargardt Disease
- Choroidemia Leber etc.
- the first group of 97 individuals, 41 males and 56 females (14 AD, 26 AR, 44 SP, 1 XL, 7 ST, 1 Refsum, 1 Kearns, 3 Usher), were treated with 4g/day of the composition of the invention.
- the second group of 74 individuals, 35 males and 39 females (9 AD, 24 AR, 34 SP, 4 ST, 1 Leber, 1 Usher, 1 XL), did not receive any treatment.
- the parameters considered to determine the efficacy of the composition of the present invention in the evaluation of the disease were the visual acuity (VA) and the visual field (VF). Such parameters were measured throughout the 8 years of duration of the study, once a year.
- Example 9 Use of the composition of the invention for treatment of retinal dystrophies non associated to genetic disorders.
- DHA increases the neuronal resistance under ischaemic conditions, reducing the optic atrophy in neuropathies and retinal dystrophy in vasculopathies. Besides the antiapoptosic effects of DHA, it has an inhibitory effect over the F2 prostaglandins.
- Drugs for glaucoma and to control the intraocular pressure (lOP) are analogue to DHA, acting as vasoconstrictor prostanoid receptors antagonists (PGF2).
- the VA before treatment was 1/10, 1/10 and 1.5/10. After 6 months the three cases increased the VA to 3/10, 6/10 y 7/10.
- the VA before suffering from CMO was 3/10, 5/10, 7/10.
- DHA increases the phototransduction and the regeneration of the rhodopsin.
- Example 11 Use of the composition on the invention for the treatment of the allergic condition, eye surface and dry eye disorders.
- DHA The effect of DHA in the eye surface gives a mechanical protective and nutritional effect, chemical protection and an antiseptic effect.
- DHA exerts a neurologic, hormonal, immunologic and anti-inflammatory control (prostaglandins).
- DHA plays an active role in the organisation of the lachrymal lipid film, reducing the evaporation of the muco-aqueous phase, reducing the surface tension of the inter-phase and as antibacterial. It inhibits apoptosis and controls the secretion of the Goblet cells. It normalises the lipid secretion and viscosity of the Meibomio glands.
- DHA acts in all types of dry eye diseases: allergies, hormonal (androgenic), infections and metabolic-dietetic in the composition of fatty acids.
- DHA inhibits the formation of dihydroxitestosterone in the lachrymal glands, increasing at the same time the androgen levels. This prevents the apoptosis of the lachrymal glands, necrosis and inflammation. DHA exerts an efficient control in the chronic inflammation, allergy and corneal oedema, since it inhibits the synthesis of leukotrienes (76%), reduces the platelet PAF, prostaglandin E2 (40%), reduction of prostaglandin F2 (81%), and controls the TNF, interleukins IL-6 and IL-Ib.
- Example 12 Treatment with the invention composition as a coadjuvant in neurology and psychiatry.
- DHA is deficient in diseases with alimentary disorders, having a determinant role both in its clinical evolution as well as in the remission such as with anorexy and bulimy, as well as in mental schizotypic disorders, personality disorders, primary attention disorders.
- DHA reduces depression, agressivness, primary attention deficit, increases memory, improves learning abilities and reduces the risk of suffering from Alzheimer.
- DHA accumulates in the brain and in the neural tissue, and the cerebral cortex is the area of the organism where it is more preserved. Its role in increasing the synapsis, in the inhibition of apoptosis in ischaemic conditions has been extensively studied.
- DHA free from phytanic acid as a coadjuvant in oncology
- PhA increases the tumoral activity, exhibits pharmacological interactions, and possibly a greater cardiovascular mortalily.
- DHA is already included as an antitumoral treatment (ie. Prostate cancer with placlitaxel) due to the numerous benefits that offers, such as the inhibition of angiogenesis, induction of apoptosis in numerous tumor lines, reduction of relapses in tumoral lines etc.
- DHA without PhA is a cofactor in oncology since:
- DHA free from PhA directly reduces the cardiotoxicity, neurotoxicity and hepatotoxicity. It has also been related to a lower hematopoietic or medular toxicity.
- DHA reduces relapses of the most prevalent tumoral lines (colorectal cancer, prostate, breast, lung, ovary, gastric, esofagic etc.)
- DHA without PhA used with retinoids are coadjuvants in treatment of lung adenocarcinoma, particularly because the absence of PhA would not induce added toxicity to retinoids.
- Retinoids and DHA have a synergic activity in certain lung cancers, mieloproliferative and colorectal cancers amongst others. DHA has been established as a chemopreventive in lung (Serini et al.,
- statins are also a chemopreventive agent and also this invention uses its association.
- PhA induces interactions with statins.
- DHA and statins have a potential effect as chemopreventive treatment in numerous and main tumors with a great epidemiological value. Their epidemiological value, still to be assessed, leads to think that currently they are important agents in the reduction of the number of cases, severity and prognosis, reduction of metastases, an increase of the therapeutic energetic intensities, delay in the evolution and in the prevention of relapses.
- DHA since it does not induce secondary effects or an added risk to the population, has other important preventive effects of great epidemiological value with age (diseases that result in blindness and dementia) and particularly since it is the only nutrient which is deficient in the general population.
- DHA free from PhA as a coadjvant to the oncologic therapy, improves the clinical conditions of the patients during a longer period and increases the statistics of the life expectancy.
- Example 14 Use of the composition of the invention in nephrology and urology
- DHA inhibits apoptosis of the nephrone, reduces ischaemic renal lesions and is a powerful renal anti- inflammatory substance in inflammatory renal diseases (nephritis, glomerulonephritis).
- DHA is an ideal coadjuvant for the multi-drug immune suppressive treatment in renal transplant.
- Dendritic cells in case of tolerance or rejection, are in charge of presenting the antigens and "the ones that decide whether there is rejection or tolerance". The modulation of dendritic cells by DHA is well known in preventing rejections, Alzheimer, autoimmune diseases, etc.
- DHA without PhA particularly reduces the risk of urine infections.
- inhibitory effect over the synthesis of DHT and particularly because is free from PhA, which is the higher risk factor for prostate cancer, benign prostate hypertrophy and alterations of the prostatic function, it is particularly efficient in the treatment and prevention of benign prostate hypertrophy and in the prevention of the erectile dysfunction.
- the creatinine value was reduced to 4.8mg/dl and it is decided to postpone the dyalisis. After 6 months with the same regime of DHA free from PhA, the creatinine levels were of 1.8mg/dl and the visual acuity of the right eye of 10/10.
- Example 14.4 Renal transplant in patient with lupus nephritis.
- Treatment with 12 g/day of DHA free from PhA is introduced, verifying after 7 days a reduction of the creatinine to 1.7mg/dl and reducing the creatinine levels to a minimum of 0.9mg/dl and an average of 1.1mg/dl during one year.
- a renal biopsy is carried out which is negative for rejection and a maintenance treatment is introduced with Prograf (7mg/day), Mycophenolate (500mg/dia) and 4g/day of DHA free from PhA.
- Prograf (7mg/day) Mycophenolate (500mg/dia)
- 4g/day of DHA free from PhA In the follow up of the next 4 years, creatinine levies remain at an average value of 1.17mg/dl with no evidence of alterations of the renal function.
- Example 14.5 Renal transplant non associated to a systemic disease.
- Example 15 Use of the composition of DHA free from PhA in autoinmune diseases, inflammatory chronic diseases and skeletal bone diseases.
- the role of DHA in chronic inflammations is widely known and has been briefly described throughout the different sections of the applications. But the most outstanding paper ih these problems is the regulation of the dendritic cells.
- the product of this invention is a coadjuvant that reduces the dose and time of use of immunesuppressors on a significant manner, particularly studied in this invention for LES, rheumatoid arthritis, juvenile arthritis, psoriasic and gout arthritis; and muscular dystrophy. It is also quite well-known the role of the product of this invention in the prevention and treatment of arthrosis and osteoporosis.
- Example 16 Use of the DHA composition free from PhA in Dermatology: Androgenic alopecia, Acne rosacea and acne vulgaris, atopic dermatitis, ichthyosis, erythrodermia, escleroderma, discoid lupus, dermatomyositis, psoriasis.
- DHT Dihydrotestosterone
- the suppression of the expression should be continuous, being possible to use lower maintenance doses (1-4 g/day).
- This treatment has the advantage against other inhibitors (ie.finasteride), that it does not reduce the levels of testosterone needed for general health and the function of the eye surface, prostate, muscular and neural tissue; being also useful for the treatment of the benign prostate hypertrophy.
- DHT from testosterone via the enzyme 5-alpha Reductase. Therefore, the uptake of DHA, based on the same mechanism previously explained for alopecia, contributes to improve acne.
- Treatment with DHA free from PhA, both in its oral and topical use over the skin, is very efficient treating acne due to its antibacterial and anti-inflammatory properties as well as to its capacity to normalise the fluid secretion of the skin sebaceous glands which is controlled by androgens, the main agents involved in acne. Therefore, the topical use over the skin 200mg/cm 2 during 20 minutes 2-5 times a week is particulary efficient against cystic acne.
- DHA from the present invention exhibits a lower allergic activity since it is possible to obtain a DHA free from PhA, from sources different to fish (cases of allergy) and of high purity, deodorised and highly reduced in peptides and derivates.
- the composition of the invention is indicated for lcthyosis (ie. harlequin icthyosis, vulgaris, congenital eritrodermia icthyosiform), since the product is free from PhA 1 an inductor of Icthyosis, and DHA's antiinfectious, immunomodulating and antiapoptosis effect, where some types of icthyosis also exhibit ocular manifestations in the eye surface and cornea.
- lcthyosis ie. harlequin icthyosis, vulgaris, congenital eritrodermia icthyosiform
- Example 17 Use of the DHA composition free in PhA in Neumology and Asthma.
- DHA increases the functional activity of such tissues, (ie. photoreceptors, neurones, lung alveoli, Purkinje cells, nephrones, dendritic cells, smoth and estriated myocites, hepatocytes, spermatozoids, ovules). Whilst DHA improves the function of such cellular types, PhA reduces their activity and normal function through the reduction of their mitochondrial activity.
- DHA is known to reduce the hypersensibility immunological response to aero-allergens which are responsible, not only for the atopic dermatitis but for lower respiratory tract diseases and asthma.
- DHA has a particular effect in the prevention of infectious diseases through the activity on dendritic cells, reducing infections and bronchial asthma.
- DHA also improves the respiratory function, being paticularly efficient in asthma and chronic respiratory diseases (EPOC).
- Treatment with DHA improves the ventilatory capacity in chronic respiratory diseases and asthma ( Kompauer et al., 2008).
- composition of the invention for the treatment of cystic fibrosis is highly recommended, since this pathology has a defficiency in DHA as well as frequent chronic infections. Since the composition of the invention is free of PhA, this results in a stronger antiinfectious effect. DHA has specific functions in the different cellular types described in this invention. However, modulation of the dendritic cells by DHA is the most relevant common mechanism of action for treatments with DHA as a coadjuvant and preventive measure in human pathologies, particularly when free of PhA, since the latter alters the function of dendritic cells and increases the sensibility to infections.
- Example 18 Use of the composition of DHA free from PhA in the Digestive system and inflammatory bowel disease (IBD)
- DHA inflammatory bowel diseases
- DHA without PhA exhibits an increased antiinfectious activity: against bacteria, virus, fungus and parasites, which can be appreciated particularly at doses beyond 4g/day.
- Many intestinal immflamatory diseases are associated to chronic infections (ej: H. pylori, Clostrodium sp., etc.).
- studies have been carried out with ulcerative colitis in adults and children, pseudomembranous colitis, Crohn's disease, collagenous colitis, irritable bowel syndrome, gastritis and esofagitis.
- DHA as a coadjuvant in the treatment of IBD with corticoids and statins enables reducing the dose of the latter and its secondary effects such as lipodystrophy.
- DHA free from PhA does not interact with statins, moreover, it particularly reduces the risk of rhabdomyolisis and the hepatopathy associated to simvastatins, therefore reducing the need to use statins, which are contraindicated in lipodystrophy associated to retroviral treatments.
- DHA reduces the hypertriglyceridemia and improves the lipoproteic profile without reducing the LDL cholesterol fraction, except at very high doses (>8g/day) or when combined with sport (Yates-A et al., 2009).
- DHA low doses
- statins ie. 5mg of simvastatine
- lipodystrophy ie. treatments with anti-retrovirals and corticoids
- Example 19 Use of the DHA composition free from PhA in Sports Medicine:
- DHA DHA
- It improves the lipoproteic profile, reduces cholesterol, plays its role in controlling the Purkinje cells when controlling the cardiac frequency and improves the ventilatory function and the aerobic metabolism in myocites.
- the DHA taken chronically in low dosages (0.5 g/day) and in the form of a structured lipid can be an important complement in replacing homeostatis during moderate and even intensive physical effort (Lopez-Roman et al., 2008).
- PhA is a particular antagonist described in this invention. So, from a theoretical viewpoint, it is expected for the DHA from this invention to have a higher activity in sports physiology.
- PhA has a powerful toxicity and causes irreversible damages in the mitochondrial electron transport chain, producing a severe reduction of the oxidative phosphorylation, being a critical point in sports performance and the aerobic, muscular and cardiovascular metabolism in sports medicine. PhA is associated with conduction delay and sudden cardiac death (M ⁇ nning et a!., 2004).
- Example 20 Use of the composition of DHA free from PhA in Thyroid pathologies.
- Tyroxine between 17 and 49 years, with and without deficiency of DHA and abnormal levels of antithyroid antibodies. After 6 months of treatment, all patients showed a significant reduction on the antithyroid antibodies and a significant reduction on the cardiac rhythm symptoms, both in hyperthyroid as well as hypothyroid patients (induced by radioactive iodine) due to treatment with thyroxine.
- Example 21 Use of the DHA composition free from PhA in Cardiovascular diseases
- DHA has an effect as cofactor in the prevention of cardiovascular risk factors, diabetes etc. it has not proved to have a significant clinical effect in the treatment of these signs. However, it has reduced the mortality and morbility in patients with cardiovascular diseases. DHA reduces the atherosclerotic effect associated to such risk factors. Particularly in diabetes, due to its antiangiogenic effect and neurotrophic factor in retina (diabetic retinopathy) and neuroprotector (diabetic neuropathy).
- the composition of the present invention has a powerful antiarrhythmic effect, particularly because is PhA free, since PhA induces conduction delay and sudden cardiac death, being more efficient than commercial DHA in several types of arrhythmia.
- the compound of the invention, DHA free from PhA is useful in the prevention of arrhythmias and thrombosis, as well as on the treatment of some vascular pathologies such as Raynaud syndrome and for the treatment of hypertrigiyceremia.
- DHA reduces the number of deaths due to cardiac failure associated to atherosclerotic pathologies, hyperglycemia, artherosclerosis associated to hypertension, diabetes and other metabolic and infectious factors related with artheriosclerosis such as high homocysteine levels and apopprotein (a).
- apo (a) levels in 2 patients with high levels (>30mg/dl) who had cerebrovascular artheriosclerosis and neurological alterations of ischaemic origin. Treatment with 4g/day reduced by 50% the apo (a) levels and normalised the cognitive function associated to the recurrent cerebral infarcts that they suffered.
- Example 22 Use of the DHA composition free of PhA in parasitic and infectious diseases.
- PhA reduces the activity of GTPases from subfamily Rho in epitelial cells and mucose membranes, favouring bacterial, fungus and parasites infections, a mechanism which is used by numerous bacterial toxins as their main infectious mechanism (Pseudomonas,
- PhA also interacts with antimitotics. Therefore, PhA activity is antagonic to that of DHA, very specific in infections, and thus, DHA free from PhA in more efficient to fight infections.
- DHA reduces bacterial infections such as that by Pseudomonas aeruginosa in lung infections mediated by the inflammatory response (Tiesset et al., 2009) and fungus infections (Bajpai et al., 2009) mediated by DHA specific docosanoids (Haas-Stapleton, et al. 2007).
- bacterious infections by Helicobacter pylori DHA has proved to be, through in vitro studies using the Kirby Bauer method, an active bactericidal substance (Drago et al., 1999). Studies in vitro and in vivo determine the antiinfectious (virus, fungus and bacteria) and antiparasitary capacity of DHA.
- DHA is severely reduced in infections by Plasmodium falciparum (Hsiao et al., 1991), and it is known that further reductions (25%) are associated to retinal degeneration, dementia and an increase in atherosclerosis associated to other risk factors. Viral infections (Rubeola) have also been associated to high levels of phytanic acid (Pike et al., 1990).
- DHA free from PhA can be used as a preventive compound and potenciator of the effects of antibiotics, reducing the cases of infections and reinfections particularity in viral and funga! infections. !n this way, the use of antibiotics is reduced, improving its epidemiologic activity and avoiding viral and fungal infections secondary to the use of antibiotics.
- the antinfectious effect of the product of this invention reduces the complications and evolution of infections of great extra-infectious and epidemiological relevance, such as the digestive pathology associated to H. pylori and decay.
- N-Tetradecanoyl is the NH2-Terminal Blocking Group of the Catalytic Subunit of Cyclic AMP-Dependent Protein Kinase from
- Bovine Cardiac Muscle Proc-Natl-Acad-Sci-USA. 1982; 79(20): 6128-31.
- Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0924012A BRPI0924012A2 (en) | 2009-04-17 | 2009-04-17 | process for obtaining an omega 3 fatty acid rich composition of an oil of marine origin, with an interior af content of 90 mg / g composition, nutritional supplement food product, pharmaceutical composition, and use of a compound |
DK09776547.3T DK2429317T4 (en) | 2009-04-17 | 2009-04-17 | Compositions with high levels of omega-3 fatty acids and with low levels of phytic acid |
US13/264,659 US9062275B2 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
EP09776547.3A EP2429317B2 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
ES09776547T ES2574136T5 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega 3 fatty acids with a low phytanic acid content |
PT97765473T PT2429317T (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
CN200980158786.7A CN102438468B (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
KR1020117027108A KR101759353B1 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
JP2012505054A JP5872453B2 (en) | 2009-04-17 | 2009-04-17 | Composition with low phytanic acid content and rich in omega-3 fatty acids |
PCT/EP2009/002842 WO2010118761A1 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
CA2756528A CA2756528A1 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
PL09776547T PL2429317T5 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
MX2011010821A MX2011010821A (en) | 2009-04-17 | 2009-04-17 | COMPOSITIONS RICH IN OMEGA-3 FATTY ACIDS WITH LOW CONTENT IN FITANIC ACID. |
AU2009344374A AU2009344374B2 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/002842 WO2010118761A1 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010118761A1 true WO2010118761A1 (en) | 2010-10-21 |
Family
ID=41279300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/002842 WO2010118761A1 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
Country Status (14)
Country | Link |
---|---|
US (1) | US9062275B2 (en) |
EP (1) | EP2429317B2 (en) |
JP (1) | JP5872453B2 (en) |
KR (1) | KR101759353B1 (en) |
CN (1) | CN102438468B (en) |
AU (1) | AU2009344374B2 (en) |
BR (1) | BRPI0924012A2 (en) |
CA (1) | CA2756528A1 (en) |
DK (1) | DK2429317T4 (en) |
ES (1) | ES2574136T5 (en) |
MX (1) | MX2011010821A (en) |
PL (1) | PL2429317T5 (en) |
PT (1) | PT2429317T (en) |
WO (1) | WO2010118761A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012103049A1 (en) * | 2011-01-25 | 2012-08-02 | Nestec S. A. | Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals |
CN102747045A (en) * | 2011-04-19 | 2012-10-24 | 华中农业大学 | Swine influenza virus H1N1 SIVTJ inactivated vaccine and preparation method thereof |
WO2013037794A1 (en) | 2011-09-12 | 2013-03-21 | Georgiou Tassos | Use of omega fatty acids for treating disease |
EP2641597A1 (en) * | 2010-11-19 | 2013-09-25 | Nippon Suisan Kaisha, Ltd. | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders |
JP2014512351A (en) * | 2011-03-29 | 2014-05-22 | パルパ・メディカル・リミテッド | Composition for the treatment of neurological disorders |
WO2014143806A1 (en) * | 2013-03-15 | 2014-09-18 | The Penn State Research Foundation | Acid stable liposomal compositions |
US9050309B2 (en) | 2012-01-06 | 2015-06-09 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
EP2881456A1 (en) | 2013-12-04 | 2015-06-10 | Natac Pharma, S.L. | Enzymatic method for separating phytanic acid from fats or oils containing it and recovering unaltered products free of phytanic acid |
WO2015165507A1 (en) * | 2014-04-29 | 2015-11-05 | Georgiou Tassos | Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio |
WO2016150936A1 (en) | 2015-03-26 | 2016-09-29 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
RU2652342C1 (en) * | 2017-07-13 | 2018-04-25 | Наталья Александровна Гаврилова | Composition for treatment of retinal neovascularization in experiment and method of treatment with its implementation |
EP2964215B1 (en) | 2013-03-08 | 2019-08-21 | Again Life Italia Srl | Mixture of fatty acids for use in the treatment of inflammatory pathologies |
US10844316B2 (en) | 2015-12-01 | 2020-11-24 | Nippon Suisan Kaisha, Ltd. | Docosahexaenoic acid-containing oil and method for producing same |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
WO2013148136A1 (en) | 2012-03-30 | 2013-10-03 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
DE202013012742U1 (en) | 2012-09-12 | 2019-01-22 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
KR102171897B1 (en) * | 2012-09-12 | 2020-11-02 | 노바리크 게엠베하 | Semifluorinated alkane compositions |
WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
PT2956056T (en) | 2013-03-14 | 2019-09-20 | Univ Laval | Electroretinography (erg) system for the assessment of psychiatric disorders |
KR102253929B1 (en) * | 2013-04-22 | 2021-05-20 | 스마트피쉬 에이에스 | Use of a composition comprising fish oil and juice for the treatment and/or post-treatment of cancer |
US20160263072A1 (en) * | 2013-10-28 | 2016-09-15 | Nestec S.A. | Monoacylglycerols and fat-soluble nutrients for use in the treatment of malabsorption having a non-mechanical basis |
ES2813383T3 (en) * | 2013-12-19 | 2021-03-23 | Tassos Georgiou | Composition of omega 3 fatty acids to treat diseases that involve damage to the nervous system |
EP3116313B1 (en) * | 2014-03-13 | 2021-06-23 | Retrotope, Inc. | Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances |
JP2016141624A (en) * | 2015-01-30 | 2016-08-08 | 有限会社ハヌマット | Prognosis improving agent for cancer patients |
SG10201912618XA (en) * | 2015-08-31 | 2020-02-27 | Nippon Suisan Kaisha Ltd | Free polyunsaturated fatty acid-containing composition and manufacturing method therefor |
CN109073648A (en) * | 2016-03-15 | 2018-12-21 | 拜尔梅里科有限公司 | Composition, equipment and the method for fibromyalgia sensitivity test |
KR20180051737A (en) * | 2016-11-08 | 2018-05-17 | 차의과학대학교 산학협력단 | Anti concer composition comprising ω-3 polyunsaturated fatty acids prevented colitis-associated carcinogenesis |
CN111182893A (en) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | Ophthalmic composition comprising F6H8 |
CN108096181A (en) * | 2018-02-05 | 2018-06-01 | 西安医学院 | DHA, EPA are in the application for the oral drugs for preparing treatment xerophthalmia |
AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
KR20210016746A (en) | 2019-08-05 | 2021-02-17 | 충남대학교산학협력단 | Anti-Toxoplasma gongii Composition Comprising Omega-3 Polyunsaturated Fatty Acids |
WO2021035178A1 (en) * | 2019-08-21 | 2021-02-25 | Burke & Boyer, Inc. | Monounsaturated fatty acid composition and use for treating fatty liver disease |
CN110846346B (en) * | 2019-11-26 | 2021-06-22 | 瞿瀚鹏 | Microbial oil rich in Sn-2 DHA, and preparation method and application thereof |
KR20210018171A (en) | 2020-11-16 | 2021-02-17 | 충남대학교산학협력단 | Anti-Toxoplasma Composition Comprising Caenorhabditis elegans fat-1 which Induces Conversion to Omega-3 Fatty Acid |
CN113584093B (en) * | 2021-07-30 | 2022-07-19 | 江南大学 | Preparation method of structured lipid with high DHA content and product thereof |
CN113995747A (en) * | 2021-10-19 | 2022-02-01 | 杭州莱樱斯生物医药科技有限公司 | A product for treating alopecia and new application of bilobalide A in treating stress induced alopecia |
KR20240094157A (en) | 2022-12-13 | 2024-06-25 | 충남대학교산학협력단 | Composition for preventing or treating Toxoplasma infection comprising Nobiletin |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2069520A (en) * | 1980-01-07 | 1981-08-26 | Nippon Oils & Fats Co Ltd | Process for separating the components of a mixture of fatty compounds |
US4792418A (en) * | 1985-08-14 | 1988-12-20 | Century Laboratories, Inc. | Method of extraction and purification of polyunsaturated fatty acids from natural sources |
US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
US4874629A (en) | 1988-05-02 | 1989-10-17 | Chang Stephen S | Purification of fish oil |
EP0347509A1 (en) | 1988-06-21 | 1989-12-27 | Century Laboratories Inc. | A process of extraction and purification of polyunsaturated fatty acids from natural sources |
ES2018384A6 (en) | 1988-08-11 | 1991-04-01 | Norsk Hydro As | Fatty acid composition |
US5013569A (en) | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
US5023100A (en) | 1988-05-02 | 1991-06-11 | Kabi Vitrum Ab | Fish oil |
ES2035751T3 (en) | 1989-04-19 | 1993-04-16 | Novo Nordisk A/S | PROCEDURE FOR PREPARING A TRIGLYCERIDE AND TRIGLYCERIDE COMPOSITION. |
ES2056852T3 (en) | 1987-05-28 | 1994-10-16 | Star Oil Ltd | A PROCEDURE FOR THE EXTRACTION OF ETHYL ESTER FROM DOCOSAHEXENOIC ACID FROM FISH OILS AND PHARMACEUTICAL AND / OR DIETARY COMPOSITIONS CONTAINING A MIXTURE OF ETHYL ESTERS OF DOCOSAHEXENOIC AND EICOSEPEN ACID. |
WO1995011216A1 (en) | 1993-10-20 | 1995-04-27 | Trikonex Ab | A process for separating lipophilic compounds |
CN1105205A (en) | 1994-01-11 | 1995-07-19 | 黄升 | Nourishing food rich in DHA and active calcium for tonifying brain and benefiting intelligence and preparing process thereof |
JPH0898659A (en) | 1994-09-30 | 1996-04-16 | Nippon Suisan Kaisha Ltd | Fish feed having improving effect on stress |
CN1130040A (en) | 1995-12-05 | 1996-09-04 | 杨学斌 | Puffed food containing DHA for invigorating brain |
US5679809A (en) | 1994-05-09 | 1997-10-21 | Nestec S.A. | Concentrate of polyunsaturated fatty acid ethyl esters and preparation thereof |
GB2350610A (en) | 1999-06-01 | 2000-12-06 | Jfs Envirohealth Ltd | Preparation of pure unsaturated fatty acids |
EP1065196A1 (en) | 1999-06-28 | 2001-01-03 | Nisshin Flour Milling Co., Ltd. | Process of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters |
CN1557453A (en) | 2004-01-29 | 2004-12-29 | 任连坤 | Memory and perception improving pure natural composite preparation and its preparing process |
US6846942B2 (en) | 2003-05-20 | 2005-01-25 | David Rubin | Method for preparing pure EPA and pure DHA |
ES2277557A1 (en) | 2005-12-21 | 2007-07-01 | Proyecto Empresarial Brudy, S.L. | Use of docosahexaenoic acid or eicosapentaenoic acid or docosahexaenoic acid-derived eicosapentaenoic acid for manufacturing pharmaceutical composition for treating pathology associated with cellular oxidative damage |
US20070299272A1 (en) * | 2006-06-27 | 2007-12-27 | Pos Pilot Plant Corporation | Process for separating saturated and unsaturated fatty acids |
US20080114181A1 (en) | 2006-11-13 | 2008-05-15 | Rajiv Manohar Banavali | Method for esterification of free fatty acids in triglycerides |
US20080268117A1 (en) | 2007-04-30 | 2008-10-30 | David Rubin | Method of purifying oils containing epa and dha |
WO2009020406A1 (en) * | 2007-08-07 | 2009-02-12 | Granate Seed Limited | Methods of making lipid substances, lipid substances made thereby and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57149400A (en) * | 1981-03-12 | 1982-09-14 | Kureha Chemical Ind Co Ltd | Manufacture of high purity long chain highly unsaturated fatty acid ester |
JPH0225447A (en) * | 1988-07-13 | 1990-01-26 | Nippon Oil & Fats Co Ltd | Production of highly unsaturated fatty acids |
US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
JP4530311B2 (en) | 2000-07-13 | 2010-08-25 | 日本水産株式会社 | Method for producing glyceride using lipase |
CN1345544A (en) * | 2000-09-29 | 2002-04-24 | 国家海洋药物工程技术研究中心 | Method for producing marine product nutrient health care egg |
NL1019368C2 (en) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparation for improving receptor performance. |
CN1378846A (en) * | 2002-03-22 | 2002-11-13 | 海南加华海产生物制药有限公司 | Shark-liver oil softgel |
PT1542670E (en) * | 2002-09-24 | 2013-07-11 | Suntory Holdings Ltd | Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults |
CN101018862B (en) * | 2004-04-22 | 2013-10-09 | 联邦科学技术研究组织 | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
BRPI0516803A (en) * | 2004-11-19 | 2008-09-23 | Martek Biosciences Corp | long chain polyunsaturated fatty acid oxylipines and their methods of production and use |
CN101213281B (en) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | New dha derivatives and their use as medicaments |
CN101262863B (en) * | 2005-07-08 | 2016-08-31 | Dsmip资产公司 | For treating the polyunsaturated fatty acid of dull-witted and front dull-witted associated conditions |
ITMI20051560A1 (en) * | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
PL1962825T3 (en) * | 2005-12-21 | 2014-09-30 | Brudy Tech S L | Use of dha for treating a pathology associated with cellular oxidative damage |
EP1996686A1 (en) * | 2006-02-07 | 2008-12-03 | Universitetet I Oslo | Omega 3 |
KR100832397B1 (en) * | 2007-02-12 | 2008-05-26 | 경북대학교 산학협력단 | Process of producing edible oil containing diacylglycerol |
CN100574772C (en) * | 2007-03-23 | 2009-12-30 | 童宥霖 | A kind of soft capsule that contains phylloxanthin and preparation method thereof |
CN101381298B (en) * | 2008-10-21 | 2011-09-07 | 四川省毛叶山桐子科技股份有限公司 | Method for preparing conjugate linolic acid using idesia polycarpa maxim. var. vestita diels oil |
EP2464240A1 (en) * | 2009-08-10 | 2012-06-20 | K.D. Pharma Bexbach GMBH | Phytanic acid fractionation process, fatty acid products and use thereof |
-
2009
- 2009-04-17 US US13/264,659 patent/US9062275B2/en active Active
- 2009-04-17 WO PCT/EP2009/002842 patent/WO2010118761A1/en active Application Filing
- 2009-04-17 EP EP09776547.3A patent/EP2429317B2/en active Active
- 2009-04-17 DK DK09776547.3T patent/DK2429317T4/en active
- 2009-04-17 KR KR1020117027108A patent/KR101759353B1/en active IP Right Grant
- 2009-04-17 JP JP2012505054A patent/JP5872453B2/en active Active
- 2009-04-17 ES ES09776547T patent/ES2574136T5/en active Active
- 2009-04-17 CN CN200980158786.7A patent/CN102438468B/en active Active
- 2009-04-17 PL PL09776547T patent/PL2429317T5/en unknown
- 2009-04-17 PT PT97765473T patent/PT2429317T/en unknown
- 2009-04-17 BR BRPI0924012A patent/BRPI0924012A2/en not_active IP Right Cessation
- 2009-04-17 MX MX2011010821A patent/MX2011010821A/en active IP Right Grant
- 2009-04-17 CA CA2756528A patent/CA2756528A1/en not_active Abandoned
- 2009-04-17 AU AU2009344374A patent/AU2009344374B2/en active Active
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2069520A (en) * | 1980-01-07 | 1981-08-26 | Nippon Oils & Fats Co Ltd | Process for separating the components of a mixture of fatty compounds |
US4792418A (en) * | 1985-08-14 | 1988-12-20 | Century Laboratories, Inc. | Method of extraction and purification of polyunsaturated fatty acids from natural sources |
ES2056852T3 (en) | 1987-05-28 | 1994-10-16 | Star Oil Ltd | A PROCEDURE FOR THE EXTRACTION OF ETHYL ESTER FROM DOCOSAHEXENOIC ACID FROM FISH OILS AND PHARMACEUTICAL AND / OR DIETARY COMPOSITIONS CONTAINING A MIXTURE OF ETHYL ESTERS OF DOCOSAHEXENOIC AND EICOSEPEN ACID. |
US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
US4874629A (en) | 1988-05-02 | 1989-10-17 | Chang Stephen S | Purification of fish oil |
US5023100A (en) | 1988-05-02 | 1991-06-11 | Kabi Vitrum Ab | Fish oil |
EP0347509A1 (en) | 1988-06-21 | 1989-12-27 | Century Laboratories Inc. | A process of extraction and purification of polyunsaturated fatty acids from natural sources |
ES2018384A6 (en) | 1988-08-11 | 1991-04-01 | Norsk Hydro As | Fatty acid composition |
US5698594A (en) * | 1988-08-11 | 1997-12-16 | Norsk Hydro A.S | Treatment and prevention of risk factors for cardiovascular diseases |
ES2035751T3 (en) | 1989-04-19 | 1993-04-16 | Novo Nordisk A/S | PROCEDURE FOR PREPARING A TRIGLYCERIDE AND TRIGLYCERIDE COMPOSITION. |
US5013569A (en) | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
WO1995011216A1 (en) | 1993-10-20 | 1995-04-27 | Trikonex Ab | A process for separating lipophilic compounds |
US5734071A (en) | 1993-10-20 | 1998-03-31 | Trikonex Ab | Process for separating lipophilic compounds |
CN1105205A (en) | 1994-01-11 | 1995-07-19 | 黄升 | Nourishing food rich in DHA and active calcium for tonifying brain and benefiting intelligence and preparing process thereof |
US5679809A (en) | 1994-05-09 | 1997-10-21 | Nestec S.A. | Concentrate of polyunsaturated fatty acid ethyl esters and preparation thereof |
JPH0898659A (en) | 1994-09-30 | 1996-04-16 | Nippon Suisan Kaisha Ltd | Fish feed having improving effect on stress |
CN1130040A (en) | 1995-12-05 | 1996-09-04 | 杨学斌 | Puffed food containing DHA for invigorating brain |
GB2350610A (en) | 1999-06-01 | 2000-12-06 | Jfs Envirohealth Ltd | Preparation of pure unsaturated fatty acids |
EP1065196A1 (en) | 1999-06-28 | 2001-01-03 | Nisshin Flour Milling Co., Ltd. | Process of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters |
US6846942B2 (en) | 2003-05-20 | 2005-01-25 | David Rubin | Method for preparing pure EPA and pure DHA |
CN1557453A (en) | 2004-01-29 | 2004-12-29 | 任连坤 | Memory and perception improving pure natural composite preparation and its preparing process |
ES2277557A1 (en) | 2005-12-21 | 2007-07-01 | Proyecto Empresarial Brudy, S.L. | Use of docosahexaenoic acid or eicosapentaenoic acid or docosahexaenoic acid-derived eicosapentaenoic acid for manufacturing pharmaceutical composition for treating pathology associated with cellular oxidative damage |
US20070299272A1 (en) * | 2006-06-27 | 2007-12-27 | Pos Pilot Plant Corporation | Process for separating saturated and unsaturated fatty acids |
US20080114181A1 (en) | 2006-11-13 | 2008-05-15 | Rajiv Manohar Banavali | Method for esterification of free fatty acids in triglycerides |
US20080268117A1 (en) | 2007-04-30 | 2008-10-30 | David Rubin | Method of purifying oils containing epa and dha |
WO2009020406A1 (en) * | 2007-08-07 | 2009-02-12 | Granate Seed Limited | Methods of making lipid substances, lipid substances made thereby and uses thereof |
Non-Patent Citations (116)
Title |
---|
ADAMICH-M; TOWLE-A; LUNAN-KD: "Ficoll density gradient separation of extracellular DDT from Chlorella", BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol. 12, no. 5, 1974, pages 562 - 6 |
ADLER-R: "Regulation of neurite growth in purified retina cultures: effects of PNPF, a substratum-bound neurite-promoting factor", J NEUROSCI RES, vol. 8, 1982, pages 165 - 177 |
ALLEN-NE; GRACE-PB; GINN-A; TRAVIS-RC; ROADDAM-AW; APPLEBY-PN; KEY-T.: "Phytanic acid: measurement of plasma concentrations by gas-liquid chromatography-mass spectrometry analysis and associations with diet and other plasma fatty acids", BR J NUTR., vol. 99, no. 3, March 2008 (2008-03-01), pages 653 - 9 |
ANDERSON-RE; MAUDE-MB; MCCLELLAN-M; MATTHES-MT; YASUMURA-D; LAVAIL-MM: "Low docosahexaenoic acid levels in rod outer segments of rats with P23H and S334ter rhodopsin mutations", MOL VIS., vol. 8, September 2002 (2002-09-01), pages 351 - 8 |
ANDREOLA-F; GIANDOMENICO-V; SPERO-R; DE LUCA-LM: "Expression of a smaller lecithin:retinol acyl transferase transcript and reduced retinol esterification in MCF-7 cells", BIOCHEM BIOPHYS RES COMMUN, vol. 279, no. 3, December 2000 (2000-12-01), pages 920 - 4 |
ARNHOLD-T; ELMAZAR-M; NAU-H: "Prevention of Vitamin A Teratogenesis by Phytol or Phytanic Acid Results from Reduced Metabolism of Retinol to the Teratogenic Metabolite, All-trans- retinoic Acid", TOXICOL SCIENCES., vol. 66, 2002, pages 274 - 282 |
AYRANCI-E; AKGUL-G.: "Apparent molar volumes and viscosities of lauric, palmitic, and stearic acids in 2-butanol at (20, 30, 40, and 60) °C", JOURNAL OF CHEMICAL AND ENGINEERING DATA, vol. 48, no. 1, 2003, pages 56 - 60 |
BAJPAI-VK; KIM-HR; HOU-CT; KANG-SC: "Microbial conversion and in vitro and in vivo antifungal assessment of bioconverted docosahexaenoic acid (bDHA) used against agricultural plant pathogenic fungi", J IND MICROBIOL BIOTECHNOL., March 2009 (2009-03-01) |
BARRAGAN-I; MARCOS-I; BORREGO-S; ANTINOLO-G.: "Molecular analysis of RIM1 in autosomal recessive Retinitis pigmentosa", OPHTHALMIC RES., vol. 37, no. 2, March 2005 (2005-03-01), pages 89 - 93 |
BAZAN-NG; SCOTT-BL; REDDY-TS; PELIAS-MZ: "Decreased Content of Docosahexaenoate and Arachidonate in Plasma Phospholipids in Usher's Syndrome", BIOCHEM-BIOPHYS-RES-COMMUN, vol. 141, no. 2, 1986, pages 600 - 4, XP001097419, DOI: doi:10.1016/S0006-291X(86)80215-7 |
BELLET-R; CARDUCCI-M; PETRYLAK-D; KASIMIS-B; IRWIN-D; MODIANO-M; MANSOUR-R; AXELROD-R; DOUKAS-M: "Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)", JOURNAL OF CLINICAL ONCOLOGY, 2004 ASCO ANNUAL MEETING PROCEEDINGS, vol. 22, pages 4657 |
BOORJIAN-S; TICKOO-SK; MONGAN-NP; YU-H; BOK-D; RANDO-RR; NANUS-DM; SCHERR-DS; GUDAS-LJ: "Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer", CLIN CANCER RES., vol. 15, no. 10, May 2004 (2004-05-01), pages 3429 - 37, XP002603752 |
BOTTINO-NR; VANDERBURG-GA; REISER-R.: "Resistance of certain long-chain polyunsaturated fatty acids of marine oils to pancreatic lipase hydrolysis", LIPIDS, vol. 2, no. 6, 1967, pages 489 - 93 |
BRITTON-TC; GIBBERD-FB; CLEMENS-ME; BILLIMORIA-JD; SIDEY-MC.: "The Significance of Plasma Phytanic Acid Levels in Adults", J-NEUROL-NEUROSURG-PSYCHIATRY, vol. 52, no. 7, 1989, pages 891 - 4 |
BROWN P J ET AL: "DIET AND REFSUN'S DISEASE. THE DETERMINATION OF PHYTANIC ACID AND PHYTOL IN CERTAIN FOODS AND THE APPLICATION OF THIS KNOWLEDGE TO THE CHOICE OF SUITABLE CONVENIENCE FOODS FOR PATIENTS WITH REFSUM'S DISEASE", JOURNAL OF HUMAN NUTRITION AND DIETETICS, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 6, no. 4, 1 January 1993 (1993-01-01), pages 295 - 305, XP009024039, ISSN: 0952-3871 * |
BROWN-PJ; MEI-G; GIBBERD-FB; BURSTON-D; MAYNE-PD; MCCLINCHY-JE; MARGARET-S: "Diet and Refsum's disease. The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease", JOURNAL OF HUMAN NUTRITION AND DIABETICS, vol. 6, no. 4, 1993, pages 295 - 305, XP009024039 |
CANAS-BJ; YURAWECZ-MP: "Ethyl carbamate formation during urea complexation for fractionation of fatty acids", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, vol. 76, no. 4, 1999, pages 537 |
CARR-SA; BIEMANN-K; SHOJI-S; PARMELEE-DC; TITANI-K.: "N-Tetradecanoyl is the NH2-Terminal Blocking Group of the Catalytic Subunit of Cyclic AMP-Dependent Protein Kinase from Bovine Cardiac Muscle", PROC-NATL-ACAD-SCI-USA, vol. 79, no. 20, 1982, pages 6128 - 31 |
CHAU-KY; SIVAPRASAD-S; PATEL-N; DONALDSON-TA; LUTHERT-PJ; CHONG-NV: "Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration", EYE, vol. 22, no. 6, June 2008 (2008-06-01), pages 855 - 9 |
CHUCAIR-AJ; ROTSTEIN-NP; SANGIOVANNI-JP; DURING-A; CHEW-EY; POLITI-LE.: "Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid", INVEST OPHTHALMOL VIS SCI., vol. 48, no. 11, November 2007 (2007-11-01), pages 5168 - 77 |
CONNOR-WE; WELEBER-RG; DEFRANCESCO-C; LIN-DS: "Wolf-DP. Sperm Abnormalities in Retinitis Pigmentosa", INVEST-OPHTHALMOL-VIS-SCI., vol. 38, no. 12, 1997, pages 2619 - 28 |
DIZHOOR-AM; CHEN-CK; OLSHEVSKAYA-E; SINELNIKOVA-W; PHILLIPOV-P; HURLEY-JB: "Role of the Acylated Amino Terminus of Recoverin in Ca(2+)-Dependent Membrane Interaction", SCIENCE, vol. 259, no. 5096, 1993, pages 829 - 32 |
DIZHOOR-AM; ERICSSON-LH; JOHNSON-RS; KUMAR-S; OLSHEVSKAYA-E; ZOZULYA-S; NEUBERT-TA; STRYER-L; HURLEY-JB; WALSH-KA: "The NH2 Terminus of Retinal Recoverin is Acylated by a Small Family of Fatty Acids", J-BIOL-CHEM., vol. 267, no. 23, 1992, pages 16033 - 6 |
DORSEY-NE.: "Viscosity of water taken from "Properties of Ordinary Water-Substance", 1940, HAFNER PUBLISHING CO., pages: 184 |
DRAGO-L; MOMBELLI-B; CIARDO-G; DE-VECCHI-E; GISMONDO-MR: "Effects of three different fish oil formulations on Helicobacter pylori growth and viability: in vitro study", J CHEMOTHER., vol. 11, no. 3, June 1999 (1999-06-01), pages 207 - 10 |
DUNSTAN JA; MORI TA; BARDEN A; BEILIN LJ; TAYLOR AL; HOLT PG; PRESCOTT SL: "Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial", J ALLERGY CLIN IMMUNOL., vol. 112, no. 6, December 2003 (2003-12-01), pages 1178 - 84 |
DUNSTAN-JA; HALE-J; BRECKLER-L; LEHMANN-H; WESTON-S; RICHMOND-P; PRESCOTT-SL: "Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-gamma responses to allergens, vaccines and colonizing skin and gut bacteria", CLIN EXP ALLERGY, vol. 35, no. 10, October 2005 (2005-10-01), pages 1309 - 17, XP055139930, DOI: doi:10.1111/j.1365-2222.2005.02348.x |
ELMAZAR-MM; NAU-H.: "Potentiation of the teratogenic effects induced by coadministration of retinoic acid or phytanic acid/phytol with synthetic retinoid receptor ligands", ARCH TOXICOL., vol. 78, no. 11, November 2004 (2004-11-01), pages 660 - 8 |
ELMAZAR-MM; RÜHL-R; NAU-H: "Synergistic teratogenic effects induced by retinoids in mice by coadministration of a RARalpha- or RARgamma-selective agonist with a RXR-selective agonist", TOXICOL APPL PHARMACOL., vol. 170, no. 1, January 2001 (2001-01-01), pages 2 - 9 |
ENGEL-J; BALACHANDRAN-P.: "Role of Pseudomonas aeruginosa type III effectors in disease", CURR OPIN MICROBIOL., vol. 12, no. 1, February 2009 (2009-02-01), pages 61 - 6, XP026194637, DOI: doi:10.1016/j.mib.2008.12.007 |
ETER-N; ALEX-AF; SPITZNAS-M; TITTEL-AP; HOLZ-FG; KURTS-C: "Inhibitory effect of epigallocatechin gallate (EGCG), resveratrol and curcumin on the proliferation of human retinal pigment epithelial cells in vitro. Symposium der International Society of Ocular Trauma", 2008, GERMAN MEDICAL SCIENCE GMS PUBLISHING HOUSE |
FABER-K.: "Biotransformations in Organic Chemistry", 2004, SPRINGER |
FENG-S; LOCK-AL; GARNSWORTHY-PC: "Technical Note: A Rapid Lipid Separation Method for Determining Fatty Acid Composition of Milk", J DAIRY SCI., vol. 87, 2004, pages 3785 - 8, XP026974753 |
FERDINANDUSSE-S; DENIS-S; CLAYTON-PT; GRAHAM-A; REES-JE; ALLEN-JT; MCLEAN-BN; BROWN-AY; VREKEN-P; WATERHAM-HR: "Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy", NAT GENET, vol. 24, 2000, pages 188 - 91, XP002231415, DOI: doi:10.1038/72861 |
FERDINANDUSSE-S; ZOMER-AW; KOMEN-JC; VAN-DER-BRINK-CE; THANOS-M; HAMERS-FP; WANDERS-RJ; VAN DER SAAG-PT; POLL-THE-BT; BRITES-P: "Ataxia with loss of Purkinje cells in a mouse model for Refsum disease", PROC NATL ACAD SCI U S A., vol. 105, no. 46, 18 November 2008 (2008-11-18), pages 17712 - 7 |
FINDERHUT-R; SCHMITZ-W; GARAVAGLIA-B; REICHMANN-H; CONZELMANN-E: "Impaired degradation of phytanic acid in cells from patients with mitochondriopathies: evidence for the involvement of ETF and the respiratory chain in phytanic acid alpha-oxidation", J INHERIT METAB DIS., vol. 17, no. 5, 1994, pages 527 - 32 |
FLEURY-C; MIGNOTTE-B; VAYSSIÈRE-JL: "Mitochondrial reactive oxygen species in cell death signaling", BIOCHIMIE, vol. 84, no. 2-3, February 2002 (2002-02-01), pages 131 - 41 |
FUENTES-ARDERIU-X; CASTINEIRAS-LACAMBRA-MJ; QUERALTÓ COMPAÑÓ-JM: "Bioquimica Clinica y Patologia Molecular.", 1998, pages: 148 - 9 |
GENTH-H; JOHANNES-H; HARTMANNA-B; HOFMANNA-F; JUSTA-I; GERHARDA-R: "Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin B", FEBS LETTERS, vol. 580, no. 14, June 2006 (2006-06-01), pages 3565 - 9 |
GUENZI-E; T6POLT-K; LUBESEDER-MARTELLATO-C; JORG-A; NASCHBERGER-E; BENELLI-R; ALBINI-A; STÜRZL-M: "The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression", EMBO J., vol. 22, no. 15, August 2003 (2003-08-01), pages 3772 - 82, XP001180805, DOI: doi:10.1093/emboj/cdg382 |
GUO-X; KNUDSEN-BS; PEEHL-DM; RUIZ-A; BOK-D; RANDO-D; RANDO-RR; RHIM-JS; NANUS-DM; GUDAS-LJ: "Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens", CANCER RES., vol. 62, no. 6, March 2002 (2002-03-01), pages 1654 - 61 |
GUO-X; NANUS-DM; RUIZ-A; RANDO-RR; BOK-D; GUDAS-LJ.: "Reduced levels of retinyl esters and vitamin A in human renal cancers", CANCER RES., vol. 61, no. 6, March 2001 (2001-03-01), pages 2774 - 81 |
GUO-X; RUIZ-A; RANDO-RR; BOK-D; GUDAS-LJ: "Esterification of all-trans-retinol in normal human epithelial cell strains and carcinoma lines from oral cavity, skin and breast: reduced expression of lecithin:retinol acyltransferase in carcinoma lines", CARCINOGENESIS, vol. 21, no. 11, November 2000 (2000-11-01), pages 1925 - 33 |
GUTIERREZ-TORRE-SM: "Retinosis Pigmentaria; Estudio Comparativo de la Metodica y Resultados del Tratamiento en España y la Union Soviética", TESIS DOCTORAL, 1994 |
GUTKNECHT-J.: "Proton/hydroxide conductance through phospholipid bilayer membranes: effects of phytanic acid", BIOCHIM BIOPHYS ACTA, vol. 898, no. 2, April 1987 (1987-04-01), pages 97 - 108, XP023509779, DOI: doi:10.1016/0005-2736(87)90028-9 |
HAAS-STAPLETON-EJ; LU-Y; HONG-S; ARITA-M; FAVORETO-S; NIGAM-S; SERHAN-CN; AGABIAN-N.: "Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1", PLOS ONE., vol. 2, no. 12, December 2007 (2007-12-01), pages 13 - 16 |
HAIM-M.: "Prevalence of Retinitis Pigmentosa and Allied Disorders in Denmark", SYSTEMIC INVOLVEMENT AND AGE AT ONSET. ACTA-OPHTHALMOL-COPENH, vol. 70, no. 4, 1992, pages 417 - 26 |
HANSEN-RP: "3,7,11,15-tetramethylhexadecanoic acid: its occurrence in the tissues of humans afflicted with Refsum's syndrome", BIOCHIM BIOPHYS ACTA, vol. 106, no. 2, October 1965 (1965-10-01), pages 304 - 10, XP023366594, DOI: doi:10.1016/0005-2760(65)90038-X |
HARRISON-RO; CARLSON-RE: "Simplified sample preparation methods for rapid immunoassay analysis of pcdd/fs in foods", 20TH INTERNATIONAL SYMPOSIUM ON HALOGENATED ENVIRONMENTAL ORGANIC POLLUTANTS AND POPS, 2000 |
HASHIMOTO-T; SHIMIZU-N; KIMURA-T; TAKAHASHI-Y: "Ide-T. Polyunsaturated Fats Attenuate the Dietary Phytol-Induced Increase in Hepatic Fatty Acid Oxidation in Mice", J. NUTR., vol. 136, April 2006 (2006-04-01), pages 882 - 6 |
HOFFMAN-DR; BIRCH-DG.: "Docosahexaenoic Acid in Red Blood Cells of Patients with X-Linked Retinitis Pigmentosa", INVEST-OPHTHALMOL-VIS-SCI., vol. 36, no. 6, 1995, pages 1009 - 18 |
HORII-N; ARATO-S; NARAYAN-B; HOSOKAWA-M; SASHIMA-T; MIYASHITA-K.: "Occurrence of conjugated cyclopropanoid acid in purified fish oil", J AM OIL CHEM SOC., vol. 84, no. 8, 2007, pages 749 - 54 |
HSIAO-LL; HOWARD-RJ; AIKAWA-M; TARASCHI-TF: "Modification of host cell membrane lipid composition by the intra-erythrocytic human malaria parasite Plasmodium falciparum", BIOCHEM J., vol. 274, 15 February 1991 (1991-02-15), pages 121 - 32 |
HSING-AW; COMSTOCK-GW; ABBEY-H; POLK-BF: "Serologic Precursors of Cancer. Retinol, Carotenoids, and Tocopherol and Risk of Prostate Cancer", J NATL CANCER INST., vol. 82, 1990, pages 941 - 6 |
IDEL-S; ELLINGHAUS-P; WOLFRUM-C; NOFER-JR; GLOERICH-J; ASSMANN-G; SPENER-F; SEEDORF-U: "Branch Chain Fatty Acids Induce Nitric Oxide-dependent Apoptosis in Vascular Smooth Muscle Cells", J BIOL CHEM., vol. 277, no. 51, December 2002 (2002-12-01), pages 49319 - 25 |
J PEDIATR, vol. 116, no. 2, February 1990 (1990-02-01), pages 320 |
JONES-RJ; HAWKINS-RE; EATOCK-MM; FERRY-DR; ESKENS-FA; WILKE-H; EVANS-TR: "A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma", CANCER CHEMOTHER PHARMACOL., vol. 61, no. 3, March 2008 (2008-03-01), pages 435 - 41, XP019561458 |
JURUKOVSKI-V; SIMON-M.: "Reduced lecithin:retinol acyl transferase activity in cultured squamous cell carcinoma lines results in increased substrate-driven retinoic acid synthesis", BIOCHIM BIOPHYS ACTA, vol. 1436, no. 3, January 1999 (1999-01-01), pages 479 - 90, XP004277082, DOI: doi:10.1016/S0005-2760(98)00154-4 |
KAHLER-S; SCH6NFELD-P; REISER-G: "The Refsum disease marker phytanic acid, a branch chain fatty acid, affects Ca2+ homeostasis and mitochondria, and reduces cell viability in rat hippocampal astrocytes", NEUROBIOL DIS., vol. 18, no. 1, February 2005 (2005-02-01), pages 110 - 8 |
KO-CH; SHEN-SC; HSU-CS; CHEN-YC: "Mitochondrial-dependent, reactive oxygen species- independent apoptosis by myricetin: roles of protein kinase C, cytochrome c, and caspase cascade", BIOCHEM PHARMACOL., vol. 69, no. 6, March 2005 (2005-03-01), pages 913 - 27, XP004772316, DOI: doi:10.1016/j.bcp.2004.12.005 |
KO-CH; SHEN-SC; LEE-TJF; CHEN-YC: "Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells", MOL CANCER THER., vol. 4, 2005, pages 281 - 90, XP002699079 |
KOKAME-K; FUKADA-Y; YOSHIZAWA-T; TAKAO-T; SHIMONISHI-Y: "Lipid Modification at the N Terminus of Photoreceptor G-protein a-Subunit [Comentarios]", NATURE, vol. 359, no. 6397, 1992, pages 749 - 52 |
KOMEN-JC; DISTELMAIER-F; KOOPMAN-WJ; WANDERS-RJ; SMEITINK-J; WILLEMS-PH: "Phytanic acid impars mitochondrial respiration through protonphoric action", CELL MOL LIFE SCI., vol. 64, no. 24, December 2007 (2007-12-01), pages 3271 - 81 |
KOMPAUER-I; DEMMELMAIR-H; KOLETZKO-B; BOLTE-G; LINSEISEN-J; HEINRICH-J.: "Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults", EUR J EPIDEMIOL., vol. 23, no. 3, 2008, pages 175 - 90, XP019572152 |
KROEMER-G; GALLUZZI-L; BRENNERC: "Mitochondrial Membrane Permeablization in Cell Death", PHYSIOL, vol. 87, 2007, pages 99 - 163 |
LAABICH-A; MANMOTO-CC; KUKSA-V; LEUNG-DW; VISSVESVARAN-GP; KARLIGA-I; KAMAT-M; SCOTT-IL; FAWZI-A; KUBOTA-R: "Protective effects of myricetin and related flavonols against A2E and light mediated-cell death in bovine retinal primary cell culture", EXP EYE RES., vol. 85, no. 1, July 2007 (2007-07-01), pages 154 - 65, XP022153837, DOI: doi:10.1016/j.exer.2007.04.003 |
LIDE-DR; MILNE-GWA: "Handbook of Data on Organic Compounds", 1994, CRC PRESS, pages: 6560 |
LIU-L; GUDAS-LJ.: "Disruption of the lecithin:retinol acyltransferase gene makes mice more susceptible to vitamin A deficiency", J BIOL CHEM., vol. 280, no. 48, December 2005 (2005-12-01), pages 40226 - 34 |
LLOYD-MD; DARLEY-DJ; WIERZBIKI-AS; THREADGILL-MD: "Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage", FEBS J., vol. 275, no. 6, March 2008 (2008-03-01), pages 1089 - 102, XP055189274, DOI: doi:10.1111/j.1742-4658.2008.06290.x |
LOPEZ-ROMAN-J; LUQUE-A; MARTINEZ-A; VILLEGAS-JA: "Modifications in oxidative damage in sportsmen after docosahexaenoic acid (DHA) ingestion", J INT SPORTS NUT, June 2008 (2008-06-01) |
M6NNING-G; WIEKOWSKI-J; KIRCHHOF-P; STYPMANN-J; PLENZ-G; FABRITZ-L; BRUNS-HJ; ECKARDT-L; ASSMANN-G; HAVERKAMP-W: "Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice", J CARDIOVASC ELECTROPHYSIOL., vol. 15, no. 11, November 2004 (2004-11-01), pages 1310 - 6 |
MARTINEZ-M.: "Severe Changes in Polyunsaturated Fatty Acids in the Brain, Liver, Kidney, and Retina in Patients with Peroxisomal Disorders", ADV-EXP-MED-BIOL., vol. 318, 1992, pages 347 - 59 |
MATSUURA-T; HASUMURA-S; NAGAMORI-S; MURAKAMI-K: "Retinol esterification activity contributes to retinol transport in stellate cells", CELL STRUCT FUNCT., vol. 24, no. 3, June 1999 (1999-06-01), pages 111 - 6 |
MCCOLL-AJ; CONVERSE-CA, LIPID STUDIES IN RETINITIS PIGMENTOSA. PROG-LIPID-RES, vol. 34, no. 1, 1995, pages 1 - 16 |
MOBLEY-JA; LEAV-I; ZIELIE-P; WOTKOWITZ-C; EVANS-J; LAM-YW; L'ESPERANCE-BS; JIANG-Z; HO-SM: "Branch Fatty Acids in Dairy and Beef Products Markedly Enhance a-Methylacyl-CoA Racemase Expression in Prostate Cancer Cells in Vitro", CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, vol. 12, August 2004 (2004-08-01), pages 775 - 83 |
MORIGUCHI-K; YOSHIZAWA-K; SHIKATA-N; YURI-T; TAKADA-H; HADA-T; TSUBURA-A: "Suppression of N-methyl-N-nitrosourea-induced photoreceptor apoptosis in rats by docosahexaenoic acid", OPHTHALMIC RES., vol. 36, no. 2, March 2004 (2004-03-01), pages 98 - 105 |
MORIGUCHI-K; YURI-T; YOSHIZAWA-K; KIUCHI-K; TAKADA-H; INOUE-Y; HADA-T; MATSUMURA-M; TSUBURA-A: "Dietary docosahexaenoic acid protects against N-methyl-N-nitrosourea-induced retinal degeneration in rats", EXP EYE RES, vol. 77, no. 2, August 2003 (2003-08-01), pages 167 - 73 |
NEUBERT-TA; JOHNSON-RS; HURLEY-JB; WALSH-KA: "The Rod Transducin Alfa Subunit Amino Terminus is Heterogeneously Fatty Acylated", J-BIOL-CHEM., vol. 267, no. 26, September 1992 (1992-09-01), pages 18274 - 7 |
NOUROOZ-ZADEH-J; PEREIRA-P: "Age-related accumulation of free polyunsaturated fatty acids in human retina", OPHTHALMIC RES., vol. 31, no. 4, 1999, pages 273 - 9 |
NUS-M; SÁNCHEZ-MUNIZ-FJ; SÁNCHEZ-MONTERO-JM: "Methodological Aspects and Relevance of the Study of Vegetable Oil, Fat and Lipoprotein Oxidation Using Pancreatic Lipase and Arylesterase Food Technol", BIOTECHNOL, vol. 44, no. 1, 2006, pages 1 - 15 |
O'BRIEN-PJ; ST JULES-RS; REEDY-TS; BAZAN-NG; ZATZ-M.: "Acylation of Disc Membrane Rhodopsin may be Nonnzymatic", J-BIOL-CHEM., vol. 262, 1987, pages 5210 - 5 |
O'BRIEN-PJ; ZATZ-M: "Acylation of Bovine Rhodopsin by [H3] Palmitic Acid", J-BIOL-CHEM., vol. 259, 1984, pages 5054 - 7 |
PAHAN-K; KHAN-M; SMITH-BT; SINGH-I: "Ketoconazole and other imidazole derivatives are potent inhibitors of peroxisomal phytanic acid alpha-oxidation", FEBS LETT., vol. 377, no. 2, December 1995 (1995-12-01), pages 213 - 6 |
PASQUALI-D; C THALLER-C; EICHELE-G: "Abnormal level of retinoic acid in prostate cancer tissues", J CLIN ENDOCRINOLOGY & METABOLISM, vol. 81, 1996, pages 2186 - 91 |
PIKE-MG; APPLEGARTH-DA; DUNN-HG; BAMFORTH-SJ; TINGLE-AJ; WOOD-BJ; DIMMICK-JE; HARRIS-H; CHANTLER-JK; HALL-JG: "Congenital rubella syndrome associated with calcific epiphyseal stippling and peroxisomal dysfunction", J PEDIATR., vol. 116, no. 1, January 1990 (1990-01-01), pages 88 - 94, XP027128280 |
POLITI-LE; BOUZAT-C; DE LOS SANTOS-EB; BARRANTES-FJ: "Heterologous retinal cultured neurons and cell adhesion molecules induce clustering of acetylcholine receptors and polynucleation in mouse muscle BC3H-1 clonal cell line", J NEUROSCI RES., vol. 43, 1996, pages 639 - 651 |
POWERS-JM ET AL.: "Cerebellar atrophy in chronic rhizomelic chondrodysplasia punctata: a potential role for phytanic acid and calcium in the death of its Purkinje cells", ACTA NEUROPATHOL (BERL), vol. 98, no. 2, August 1999 (1999-08-01), pages 129 - 34 |
PULLARKAT-RK; REHA-H; PATEL-VK; GOEDEL-HH: "Ceroid-Lipofuscinosis: Batten's Disease", 1982, ELSEVIER-BIOMEDICAL-PRESS, pages: 335 - 43 |
RATNAYAKE-WMN; OLSSON-B; ACKMAN-RG: "Novel branched-chain fatty acids in certain fish oils", LIPIDS, vol. 24, no. 7, 1989, pages 630 - 7, XP035175020, DOI: doi:10.1007/BF02535080 |
REISER-G; SCH6NFELD-P; KAHLERT-S: "Mechanism of toxicity of the branch-chain fatty acid phytanic acid, a marker of Refsum disease, in astrocytes involves mitochondrial impairment.", INT J DEV NEUROSCI., vol. 24, no. 2-3, March 2006 (2006-03-01), pages 113 - 22 |
ROTSTEIN-NP; AVELDANO-MI; BARRANTES-FJ; ROCCAMO-AM; POLITI-LE: "Apoptosis to Retinal Photoreceptors During Development In Vitro: Protective Effect of Docosahexaenoic Acid", J NEUROCHEM., vol. 69, no. 2, 1997, pages 504 - 13 |
ROTSTEIN-NP; POLITI-LE; GERMAN-OL; GIROTTI-R: "Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors", INVEST OPHTHALMOL VIS SCI, vol. 44, no. 5, May 2003 (2003-05-01), pages 2252 - 9 |
SCH6NFELD P; REISER G: "Rotenon-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria", J BIOL CHEM., vol. 281, no. 11, 17 March 2006 (2006-03-17), pages 7136 - 42 |
SCH6NFELD-P; KAHLERT-S; REISER-G.: "In brain mitochondria the branch-chain fatty acid phytanic acid impairs energy transduction and sensitizes for permeability transition", BIOCHEM J., vol. 383, 2004, pages 121 - 8 |
SCH6NFELD-P; WOITCZAK-L: "Fatty acids decrease mitochondrial generation of reactive oxygen species at the reverse", BIOCHIM BIOPHYS ACTA, vol. 1767, no. 8, August 2007 (2007-08-01), pages 1032 - 40 |
SCHAEFER-EJ; ROBINS-SJ; PATTON-GM; SANDBERG-MA; WEIGEL-DIFRANCO-CA; ROSNER-B; BERSON-EL: "Red Blood Cell Membrane Phosphatidylethanolamine Fatty Acid Content in Various Forms of Retinitis Pigmentosa", J-LIPID-RES., vol. 36, no. 7, 1995, pages 1427 - 33 |
SCHÖNFELD P; KAHLERT S; REISER G: "A study of the cytotoxicity of branched-chain phytanic acid with mitochondria and rat brain astrocytes", EXP GERONTOL., vol. 41, no. 7, July 2006 (2006-07-01), pages 688 - 96, XP025083313, DOI: doi:10.1016/j.exger.2006.02.013 |
SERINI S; TROMBINO S; OLIVA F; PICCIONI E; MONEGO G; RESCI F; BONINSEGNA A; PICCI N; RANELLETTI FO; CALVIELLO G.: "Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression", APOPTOSIS, vol. 13, no. 9, September 2008 (2008-09-01), pages 1172 - 83, XP019599268 |
SERKOV IV; GRIGOR'EV VV; IVANOVA TA; GRETSKAYA NM; BEZUGLOV VV; BACHURIN SO: "Effect of derivatives of docosahexaenoic acid on AMPA receptors in Purkinje neurons", DOKL BIOL SCI., vol. 411, November 2006 (2006-11-01), pages 434 - 5, XP019464909, DOI: doi:10.1134/S0012496606060020 |
SHEREN-MANOFF-M; SHIN-SJ; SU-D; BOK-D; RANDO-RR; GUDAS-LJ.: "Reduced lecithin:retinol acyltransferase expression in human breast cancer", INT J ONCOL., vol. 29, no. 5, November 2006 (2006-11-01), pages 1193 - 9 |
SHUCHENG-L; CHAOHUA-Z; PENGZHI-H; HONGWU-J: "Concentration of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) of tuna oil by urea complexation: optimization of process parameters", J FOOD ENGINEERING, vol. 73, no. 3, 2006, pages 203 - 9 |
SIMMONS-DP; ANDREOLA-F; DE LUCA-LM.: "Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters", CARCINOGENESIS, vol. 23, no. 11, November 2002 (2002-11-01), pages 1821 - 30 |
STEINBERG-D.: "Refsum disease. The Metabolic and Molecular Bases of Inherited Disease", vol. 2, 1995, MCGRAW-HILL, pages: 2351 - 69 |
THORNBURG-T; TURNER-AR; CHEN-YQ; VITOLINS-M; CHANG-B; XU-J: "Phytanic acid, AMACR and prostate cancer risk", FUTURE ONCOL., vol. 2, no. 2, April 2006 (2006-04-01), pages 213 - 23 |
TUCKER-B; KLASSEN-H; YANG-L; CHEN-DF; YOUNG-MJ: "Elevated MMP Expression in the MRL Mouse Retina Creates a Permissive Environment for Retinal Regeneration", INVEST OPHTHALMOL VIS SCI., vol. 49, no. 4, April 2008 (2008-04-01), pages 1686 - 95 |
VOSS-A; REINHART-M; SPRECHER-H: "Differences in the Interconversion between 20- and 22-Carbon (n - 3) and (n - 6) Polyunsaturated Fatty Acids in Rat Liver", BIOCHIM-BIOPHYS-ACTA, vol. 1127, no. 1, 1992, pages 33 - 40, XP023577622, DOI: doi:10.1016/0005-2760(92)90198-5 |
WALLSTR6M-P; BJARTELL-A; GULLBERG-B; OLSSON-H; WIRFÄLT-E: "A prospective study on dietary fat and incidence of prostate cancer (Malm6, Sweden)", CANCER CAUSES CONTROL., vol. 18, no. 10, December 2007 (2007-12-01), pages 1107 - 21, XP019524561, DOI: doi:10.1007/s10552-007-9050-4 |
WALSH-PC: "Serum levels of phytanic acid are associated with prostate cancer risk", J UROL., vol. 174, no. 5, November 2005 (2005-11-01), pages 1824, XP025377157, DOI: doi:10.1016/S0022-5347(01)68790-1 |
WELEBER-RG; TONGUE-AC; KENNAWAY-NG; BUDDEN-SS; BAIST-NRM: "Ophthalmic Manifestations of Infantile Phytanic Acid Storage Disease", ARCH-OPHTHALMOL, vol. 102, 1984, pages 1317 - 21 |
WIELOCH-T; MATTIASSON-G; HANSSON-MJ; ELMER-E: "Handbook of Neurochemistry and Molecular Neurobiology. Brain Energetics. Int Mol Cel Processes", 2007, SPRINGER, pages: 667 - 702 |
WONG-F.: "Investigating Retinitis Pigmentosa: A Laboratory Scientists Perspective", PROG-RETINAL-EYE-RES., vol. 16, no. 3, 1997, pages 353 - 73, XP005846227, DOI: doi:10.1016/S1350-9462(96)00032-8 |
XU-J; THOMBURG-T; TURNER-AR; VITOLINS-M; CASE-D; SHADLE-J; HINSON-L; SUN-J; LIU-W; CHANG-B: "Serum levels of phytanic acid are associated with prostate cancer risk", PROSTATE, vol. 63, May 2005 (2005-05-01), pages 209 - 214 |
YATES-A: "Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players", SPORT HEALTH., 2009 |
YOSHIZAWA-K; TSUBURA-A.: "Characteristics of N-methyl-N-nitrosourea-induced retinal degeneration in animals and application for the therapy of human retinitis pigmentosa", NIPPON GANKA GAKKAI ZASSHI., vol. 109, no. 6, June 2005 (2005-06-01), pages 327 - 37 |
YUE-J; THEWALT-JL; CUSHLEY-RJ.: "Deuterium nuclear magnetic resonance study of the interaction of branched chain compounds (phytanic acid, phytol) with a phospholipid model membrane", CHEM PHYS LIPIDS., vol. 49, no. 3, December 1988 (1988-12-01), pages 205 - 13, XP024783437, DOI: doi:10.1016/0009-3084(88)90008-4 |
ZHAN-HC; GUDAS-LJ; BOK-D; RANDO-R; NANUS-DM; TICKOO-SK: "Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney", CLIN CANCER RES., vol. 9, no. 13, October 2003 (2003-10-01), pages 4897 - 905, XP002603753 |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997973A (en) * | 2010-11-19 | 2016-10-12 | 日本水产株式会社 | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders |
EP2641597A1 (en) * | 2010-11-19 | 2013-09-25 | Nippon Suisan Kaisha, Ltd. | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders |
EP2641597A4 (en) * | 2010-11-19 | 2014-04-30 | Nippon Suisan Kaisha Ltd | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders |
JPWO2012067224A1 (en) * | 2010-11-19 | 2014-05-19 | 日本水産株式会社 | Treatment or prevention agent for corneal epithelial disorder and / or conjunctival epithelial disorder |
US9320759B2 (en) | 2011-01-25 | 2016-04-26 | Nestec S.A | Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals |
WO2012103049A1 (en) * | 2011-01-25 | 2012-08-02 | Nestec S. A. | Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals |
JP2014512351A (en) * | 2011-03-29 | 2014-05-22 | パルパ・メディカル・リミテッド | Composition for the treatment of neurological disorders |
CN102747045B (en) * | 2011-04-19 | 2013-12-18 | 华中农业大学 | Swine influenza virus H1N1 SIVTJ inactivated vaccine and preparation method thereof |
CN102747045A (en) * | 2011-04-19 | 2012-10-24 | 华中农业大学 | Swine influenza virus H1N1 SIVTJ inactivated vaccine and preparation method thereof |
WO2013037794A1 (en) | 2011-09-12 | 2013-03-21 | Georgiou Tassos | Use of omega fatty acids for treating disease |
US9050309B2 (en) | 2012-01-06 | 2015-06-09 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US9050308B2 (en) | 2012-01-06 | 2015-06-09 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US10117844B2 (en) | 2012-01-06 | 2018-11-06 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
EP3219316B1 (en) | 2013-03-08 | 2020-02-19 | Again Life Italia Srl | Mixture of fatty acids (f.a.g., fatty acids group) for use in the treatment of inflammatory pathologies |
EP2964215B1 (en) | 2013-03-08 | 2019-08-21 | Again Life Italia Srl | Mixture of fatty acids for use in the treatment of inflammatory pathologies |
WO2014143806A1 (en) * | 2013-03-15 | 2014-09-18 | The Penn State Research Foundation | Acid stable liposomal compositions |
WO2015082294A1 (en) * | 2013-12-04 | 2015-06-11 | Natac Pharma S.L. | Enzymatic method for separating phytanic acid from fats or oils containing it and recovering unaltered products free of phytanic acid |
EP2881456A1 (en) | 2013-12-04 | 2015-06-10 | Natac Pharma, S.L. | Enzymatic method for separating phytanic acid from fats or oils containing it and recovering unaltered products free of phytanic acid |
WO2015165507A1 (en) * | 2014-04-29 | 2015-11-05 | Georgiou Tassos | Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio |
WO2016150936A1 (en) | 2015-03-26 | 2016-09-29 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
US10821090B2 (en) | 2015-03-26 | 2020-11-03 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
US11154525B2 (en) | 2015-03-26 | 2021-10-26 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
US10844316B2 (en) | 2015-12-01 | 2020-11-24 | Nippon Suisan Kaisha, Ltd. | Docosahexaenoic acid-containing oil and method for producing same |
US11525103B2 (en) | 2015-12-01 | 2022-12-13 | Nippon Suisan Kaisha, Ltd. | Docosahexaenoic acid-containing oil and method for producing same |
RU2652342C1 (en) * | 2017-07-13 | 2018-04-25 | Наталья Александровна Гаврилова | Composition for treatment of retinal neovascularization in experiment and method of treatment with its implementation |
Also Published As
Publication number | Publication date |
---|---|
PL2429317T3 (en) | 2016-09-30 |
ES2574136T5 (en) | 2019-08-30 |
KR20120039521A (en) | 2012-04-25 |
DK2429317T3 (en) | 2016-07-18 |
ES2574136T3 (en) | 2016-06-15 |
BRPI0924012A2 (en) | 2019-09-24 |
AU2009344374A1 (en) | 2011-10-27 |
EP2429317B2 (en) | 2019-02-20 |
EP2429317B1 (en) | 2016-03-30 |
EP2429317A1 (en) | 2012-03-21 |
US9062275B2 (en) | 2015-06-23 |
CN102438468B (en) | 2014-06-04 |
PT2429317T (en) | 2016-07-22 |
CA2756528A1 (en) | 2010-10-21 |
DK2429317T4 (en) | 2019-05-13 |
JP2012523823A (en) | 2012-10-11 |
JP5872453B2 (en) | 2016-03-01 |
MX2011010821A (en) | 2012-01-20 |
PL2429317T5 (en) | 2019-09-30 |
CN102438468A (en) | 2012-05-02 |
US20120053242A1 (en) | 2012-03-01 |
KR101759353B1 (en) | 2017-07-18 |
AU2009344374B2 (en) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2429317B1 (en) | Compositions rich in omega-3 fatty acids with a low content in phytanic acid | |
US7179491B1 (en) | Process of converting rendered triglyceride oil from marine sources into bland, stable oil | |
US20040209953A1 (en) | Glyceride compositions and methods of making and using same | |
JP4948605B2 (en) | Fish oil-derived glyceride oil composition and method for producing the same | |
US7417071B2 (en) | Antioxidant triacylglycerols and lipid compositions | |
US9273267B2 (en) | Method of treating an edible oil | |
EP1583433A1 (en) | Preparations containing polyunsaturated phospholipids, monoterpenes and optionally tryptophan and/or phytol derivatives | |
Karuna et al. | Vegetable oil-based nutraceuticals | |
ES2816008T3 (en) | DHA-enriched polyunsaturated fatty acid compositions | |
EP2273895B1 (en) | Compositions comprising myristic acid, fatty acids comprising a conjugated diene n 5cis, n 7trans or a conjugated triene n 5cis, n 7trans, n 9cis | |
JP5066857B2 (en) | Liver lipid reducing agent | |
CA2346407C (en) | Process of converting rendered triglyceride oil from marine sources into bland, stable oil | |
de Almeida et al. | GENERAL ASPECTS OF PALMITIC ACID | |
JP2008247791A (en) | Agent for ameliorating liver function | |
FR2929515A1 (en) | Use of two different fatty acids having different carbon atoms, as medicine and to prepare food, pharmaceutical or nutraceutical composition to prevent/treat chronic low-grade systemic inflammation and treat subjects having e.g. obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980158786.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09776547 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2756528 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/010821 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012505054 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009776547 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009344374 Country of ref document: AU Date of ref document: 20090417 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117027108 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13264659 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924012 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0924012 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111013 |